Diabetic Peripheral Neuropathy: The Broader Complication Burden

Summary: This BMJ article provides an updated overview of diabetic peripheral neuropathy (DPN), emphasising its systemic impact. Beyond diabetic foot ulcers, DPN contributes to increased risk of falls, fractures, cardiovascular autonomic neuropathy, and reduced quality of life. The review stresses early screening, glycaemic control, and comprehensive multidisciplinary management to mitigate the full spectrum of complications.

Key Highlights:

• DPN linked to higher rates of falls, fractures, and hospitalisations
• Strong association with cardiovascular autonomic dysfunction
• Need for broader complication screening in diabetic patients
• Importance of early intervention and patient education

Read full article

Keywords: diabetic peripheral neuropathy, DPN complications

Global Preventive Foot Care

Summary: 2025 document from Wound Canada provides a global view on preventive foot care. Focuses on high-risk groups (diabetes, neuropathy, PAD, elderly); strategies: Annual screening (monofilament, tuning fork, vascular checks), patient education (self-care, footwear), offloading (custom orthotics, shoes), multidisciplinary teams, policy advocacy. Addresses disparities (low-resource settings, cultural barriers), evidence-based tools (IWGDF guidelines), and prevention’s role in reducing DFU/amputation burden. Calls for standardized global approaches, research, and implementation to improve outcomes equitably.

Read document

Keywords: global foot care, DFU prevention, screening strategies

Implementation Strategies for the Prevention and Management of Diabetes-Related Foot Disease: A Consensus Document

Summary: This international consensus document translates evidence-based guidelines into actionable implementation strategies for diabetes-related foot disease. It covers systematic screening, risk stratification, patient education, therapeutic offloading, timely vascular intervention, infection management, and integrated multidisciplinary pathways. The document aims to bridge the gap between guidelines and real-world clinical practice to reduce ulcers, amputations, and mortality.

Key Highlights:

• Clear pathways for annual screening and risk stratification
• Practical offloading and footwear recommendations
• Emphasis on rapid access to multidisciplinary teams
• Strategies to overcome implementation barriers in different settings

Read full consensus document

Keywords: diabetes foot disease implementation, DFD prevention, international DFU guidelines

Frailty Progression and Outcomes in Patients with Diabetic Foot Ulcers

Summary: A prospective study published in Surgery (August 13, 2025) by Hong et al. from USC Keck School of Medicine examined frailty development in patients with diabetic foot ulcers (DFUs) over a 12-month period. Using the Clinical Frailty Scale, researchers followed 178 individuals to track frailty progression and its impact on clinical outcomes.

Key Findings:

• At baseline, 42% of participants were frail and remained so after one year; 25% of those initially nonfrail developed frailty.
• Baseline frailty was significantly associated with peripheral artery disease, myocardial infarction, and non-Hispanic ethnicity.
• Progression to frailty among nonfrail participants was linked to peripheral artery disease (OR 4.64), nonhealing ulcers (OR 2.96), revascularization (OR 9.09), and DFU-related hospitalizations (OR 1.96).

Implications: Frailty frequently persists in DFU patients but can also develop over time. Routine frailty screening and proactive interventions—such as improving circulation, preventing hospitalizations, and supporting wound healing—may help reduce adverse outcomes.

Read the full article on Diabetic Foot Online

Keywords:
frailty progression,
diabetic foot ulcers,
Clinical Frailty Scale,
peripheral artery disease,
wound hospitalizations,
rehabilitation strategies,
USC Keck School of Medicine

Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients: Evidence from a Hospital-Based Study in Rajshahi, Bangladesh

Summary: This 2026 cross-sectional study analyzed 159 type 2 diabetes patients with foot ulcers at Rajshahi Diabetic Association General Hospital. Severe ulcers (Wagner grades 3–5) occurred in 63.5% of cases and were associated with higher BMI, longer ulcer duration, greater treatment costs, and increased prevalence of peripheral arterial disease (PAD), peripheral neuropathy (PN), poor glycemic control, and prior amputation. Using Firth’s penalized logistic regression, independent predictors of severity were older age, poor glycemic control, PN, PAD, and prior amputation. The predictive model showed excellent performance (AUC 0.924, accuracy 85.5%). The findings emphasize the importance of early screening and aggressive management of modifiable risk factors to prevent progression to severe diabetic foot ulcers and reduce amputation risk in similar settings.

Key Highlights:

• 63.5% of DFU cases classified as severe (Wagner 3–5)
• Independent risk factors: older age, poor glycemic control, PN, PAD, prior amputation
• Strong predictive model (AUC 0.924) with good clinical utility
• Authors: Shah Tanzen Jahan, Durga H. Kutal, Anicha Akter, Md. Selim Reza, Md. Kabirul Islam

Read full article (open access)

Keywords: DFU severity, risk factors diabetic foot, peripheral neuropathy, peripheral arterial disease, Shah Tanzen Jahan

Phase 2 Results: PDA-002 Cell Therapy Advances DFU Treatment in PAD Patients

Full Press Release:

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease

Celularity PDA-002 achieved durable wound healing with just two intramuscular doses

As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients.

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial,” in the International Wound Journal. Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. Celularity’s Chairman and CEO, Robert J. Hariri, M.D., Ph.D., also commented on PDA-002 as a stem cell therapy which qualifies under a recently enacted Florida law expanding access in the state to stem cell therapies not yet approved by the U.S. Food and Drug Administration.

Approximately two million individuals in the United States are affected each year by diabetic foot ulcers (DFU), nearly half of whom have coexisting peripheral artery disease (PAD). DFU complicated by PAD represents one of the most difficult and costly challenges in wound care. Currently, there are no U.S. Food and Drug Administration (FDA)-approved therapies specifically indicated for DFU with PAD. The estimated annual economic burden of treating DFU alone exceeds $9 billion in the United States. The presence of PAD significantly compromises lower-extremity perfusion, leading to chronic tissue ischemia, impaired angiogenesis, and delayed wound repair. PAD-associated DFUs are further characterized by persistent inflammation, altered immune response, and diminished responsiveness to standard wound care interventions. Despite five FDA-approved DFU therapies, none are currently approved for DFU complicated by PAD, underscoring the need for novel regenerative approaches that restore tissue perfusion and accelerate wound closure.

The published study included 159 adult patients with chronic diabetic foot ulcers (both with and without PAD) and was conducted across 35 clinical sites in the United States. Participants received two intramuscular doses of either PDA-002, a placenta-derived cell therapy developed by Celularity, at one of three dosage levels (3 × 10⁶, 10 × 10⁶, or 30 × 10⁶ cells), or a placebo. The primary efficacy endpoint was the number of patients who achieved complete wound closure within three months with healing that remained intact for at least four additional weeks—a more rigorous measure of durability than the standard FDA definition, which requires only two weeks of durable healing.

In patients with PAD, the highest rates of wound closure were observed with the lowest PDA-002 dose (3 × 10⁶ cells), where 38.5% of ulcers completely healed versus 22.6% in the placebo group. The data also showed faster and more sustained healing in treated patients along with fewer cases of new gangrene and foot infections compared to those who received a placebo. Across all groups, PDA-002 was well tolerated, with no serious side effects linked to the treatment. This favorable safety profile remained consistent through two years of follow-up.

The study’s findings highlight the regenerative and angiogenic potential of PDA-002 in promoting durable ulcer closure in patients with DFUs complicated by PAD, using only two doses and no retreatment.

” The publication of our PDA-002 Phase 2 results in the International Wound Journal is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “Our data show that our investigational therapy, PDA-002, a placenta-derived, mesenchymal stromal-like cell therapy, can drive meaningful wound closure rates, reduce serious complications, and do so with a favorable safety profile. We believe PDA-002 has potential to transform the future of ischemic wound care, and these findings position us for a confirmatory Phase 3 trial aimed at delivering the first FDA-approved targeted therapy in regenerative wound care for DFU/PAD patients with this urgent and unmet need. We also believe these clinical results support additional development in clinical indications where underlying microvascular disease is a contributing factor.”

Commenting on recent developments, Dr. Hariri said, “Celularity is actively assessing opportunities to apply these findings in jurisdictions such as Florida, where PDA-002 qualifies as a stem cell therapy under a new law authorizing use by Florida physicians in wound care, orthopedics, and pain management.” Diabetes afflicts an estimated 2.1 million Floridians according to a January 2025 Florida Diabetes Advisory Council report, which found that the percentage of adult Floridians diagnosed with diabetes grew by almost half since 2002 and is now above the national average (12.2% versus 11.6%). That percentage jumps to 25.4% among Floridians ages 65 and older, or some 1.25 million people, a fifth to a third of whom will go on to develop a DFU, for which the 5-year recurrence rate is 65%. “By unleashing promising stem cell therapies like PDA-002, Florida has given physicians a potentially important new tool for the treatment of diabetic foot ulcers, a serious condition that afflicts over a quarter of a million Floridians ages 65 and older,” said Dr. Hariri.

About PDA-002

PDA-002 is a mesenchymal stromal-like cell therapy product derived from the postpartum placenta. These cells possess potent angiogenic, immunomodulatory, and tissue-repair properties, offering a novel approach to wound healing in patients for whom current therapies are inadequate.

About Celularity Inc.

Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies targeting fundamental aging mechanisms, such as cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.

Forward Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products, including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise, except as otherwise required by law.

Carlos Ramirez

Senior Vice President, Celularity Inc.

Carlos.ramirez@celularity.com

(908) 845-4181

Key Highlights:

• Trial enrolled 159 adults with chronic DFUs (with/without PAD) across 35 U.S. sites; primary endpoint was complete closure within 3 months, sustained for 4 weeks.
• In PAD patients, low-dose PDA-002 achieved 38.5% healing vs. 22.6% placebo, with quicker onset and durability, requiring no retreatment.
• Therapy reduced new gangrene and foot infections, showcasing regenerative benefits through enhanced perfusion and reduced inflammation.
• Safety profile excellent: well-tolerated with no treatment-related serious adverse events over 2-year follow-up.
• Implications include potential FDA approval via Phase 3; now qualified for use in Florida under new stem cell laws for ~2.1M diabetic residents.

Read full article

Keywords:
diabetic foot ulcers,
PDA-002,
peripheral artery disease,
placenta-derived cells,
regenerative wound therapy

From Healing to Remission: A Clinician’s Guide to Managing Diabetic Foot Ulcers

Summary: A new article on Medscape reframes diabetic foot ulcer (DFU) care by encouraging clinicians to view a healed ulcer not as an endpoint, but as a remission state—one that demands ongoing prevention, monitoring, and patient education. The piece outlines proactive strategies to reduce ulcer recurrence, preserve limb function, and sustain long-term patient engagement.

Key Highlights:

• Language shift: Using the term “in remission” instead of “healed” helps patients stay aware that DFU is a chronic condition with high risk of recurrence.
• Structured limb-preservation plans: Follow-ups every 1-3 months in the first year post-healing, plus risk-based intervals afterward, with regular vascular assessments especially up through 18 months post-closure.
• Prevention tools: Thermometry, remote monitoring of temperature/exudate/pressure/moisture, and protective footwear become central components of follow-up care.
• Self-management: Patients (or caregivers) should perform daily inspections, recognizing early signs, even in the absence of overt sores; lifestyle moderators like glucose, lipids, and BP control also critical.
• Psychosocial support: Screening for depression, social isolation, and other mental health or socio-economic factors that otherwise undermine preventive behaviors and healing maintenance.
• Implementation challenges: Shifting to a remission model requires clinic protocol changes, multidisciplinary coordination, and policies that recognize the long-term burden of DFUs and CLTI (chronic limb threatening ischemia).

Read the full article on Medscape

Keywords:
diabetic foot ulcer,
remission model,
limb preservation plan,
thermometry,
patient self-care,
psychosocial support

Silent and Sinister: High Prevalence of Silent, Severe Coronary Ischemia in Patients with Diabetic Foot Ulcers

Summary: A recent study published in *Journal of Vascular Surgery* (Monahan et al., 2025) found that a large portion of patients with diabetic foot ulcers (DFUs), even without prior known coronary artery disease or symptoms, have **silent but severe coronary ischemia** detectable on advanced imaging. This suggests underrecognized cardiovascular risk in the DFU population and possible need to integrate cardiac screening into comprehensive care.

Key Highlights:

• Among selected DFU patients who underwent coronary CT angiography (cCTA), more than half showed functional evidence of severe coronary disease via CT-derived fractional flow reserve (FFRct ≤ 0.75).
• Some patients required coronary intervention following catheterization despite no history of cardiac disease or symptoms.
• Suggests that DFU should be treated not only as a local wound issue but as a marker of systemic vascular disease.

Read the full article on DiabeticFootOnline

Keywords:
diabetic foot ulcer,
coronary ischemia,
silent ischemia,
CT-angiography,
Monahan et al.,
vascular risk

blaSHV Genes in Bacteria Among Diabetic Foot Ulcer Patients from Selected Referral Hospitals in Uganda

Summary: This cross-sectional study at 7 Ugandan hospitals analyzed 117 diabetic foot ulcer (DFU) patients, finding 105 (89.7%) positive for bacterial growth, predominantly Gram-negative (E. coli, Klebsiella). ESBL production was 37.1% (39/105), with blaSHV genes in 71.8% of ESBL isolates, driving high resistance to cephalosporins (90%) and amoxicillin (95%). Gram-positives like S. aureus showed MRSA at 20%. The findings underscore the need for routine ESBL screening, antibiotic stewardship, and surveillance in DFU management to curb infection-driven amputations in low-resource settings.

Key Highlights:

• Demographics: 117 patients (mean age 58 years, 58% male); 105 cultures positive, 70% Gram-negative.
• ESBL Prevalence: 37.1%; blaSHV (28/39), blaTEM (24/39); multi-drug resistance in 82% ESBL producers.
• Resistance Patterns: 90% to 3rd-gen cephalosporins; 95% to amoxicillin; carbapenems effective (85%).
• Site Variation: Higher ESBL in urban hospitals (Kiruddu 50%, Fort Portal 46%); S. aureus in 30%.
• Implications: Urgent stewardship; molecular surveillance for DFU pathogens to guide therapy and reduce amputations.

Read full article

Keywords: blaSHV genes, ESBL, diabetic foot ulcers, antibiotic resistance, Uganda DFU

A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

Summary: This narrative review examines the multifactorial pathogenesis of diabetic foot ulcers (DFUs), affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, peripheral neuropathy, hyperglycemia-induced immune defects, and microbial dysbiosis with biofilms. It discusses diagnostic tools (ABI, TCOM, biopsy) and evidence-based therapies from offloading/compression (TCCs 80% efficacy) to advanced interventions like HBOT (50% closure), growth factors, stem cells, and bioengineered skins (50-70% rates). Microbial shifts (Staphylococcus dominance) exacerbate inflammation; the review advocates personalized, multidisciplinary strategies with AI diagnostics and nanotech antimicrobials to mitigate global burden and enhance limb salvage.

Key Highlights:

• Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection in 60% of cases.
• Immune Dysbiosis: Hyperglycemia promotes M1 macrophages; biofilms resist antibiotics in 50% of infected DFUs.
• Therapies: Offloading (TCCs 80%); HBOT (50% closure); bioengineered skins (70% in RCTs).
• Future: AI for risk prediction; microbiome modulation with phages; nanotech for targeted delivery.
• Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading cuts risk 50%.

Read full article

Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins, Abdullah Al-Rubaish, Mohammed Al-Rubaish, Ahmad Al-Rubaish

Revolutionising Diabetic Foot Care: A System in Urgent Need of Reform

Summary: This editorial critiques the UK’s diabetic foot services, where only 30% of DFUs heal in 6 weeks vs 80% target, due to fragmented care and underfunding. Proposes national MDT hubs, mandatory education, and £100M investment for screening/offloading to cut 5,000 annual amputations.

Key Highlights:

• Crisis: 7,000 amputations/year; £1B cost; 30% 6-week healing.
• Gaps: No MDT in 40% services; poor education; delayed referrals.
• Reform: National hubs, £100M funding, mandatory training.
• Outcomes: Potential 50% amputation reduction with overhaul.
• Authors: Carré A, Macfarlane R, Game F et al.

Read editorial

Keywords: diabetic foot reform, UK, MDT hubs, amputation reduction, funding, A Carré, R Macfarlane, F Game

Simplified and Comprehensive Diabetic Foot Ulcer Guidelines

Summary: March 2026 article presents simplified yet comprehensive guidelines for diabetic foot ulcer (DFU) management. Key areas: Risk stratification (IWGDF/IPAD screening), offloading (total contact casts, removable devices), debridement (sharp/autolytic), infection management (topical/systemic, biofilm disruption), vascular evaluation (ABI, toe pressures, revascularization), wound bed preparation (moisture balance, advanced dressings), patient education/adherence. Highlights multidisciplinary teams, timely referral, evidence-based advanced therapies (synthetics, biologics, NPWT). Simplified for primary care use; comprehensive for specialists. Emphasizes prevention, early intervention, and amputation reduction through standardized pathways and patient-centered care.

Read abstract (subscription may be required)

Keywords: DFU guidelines, diabetic foot ulcer, offloading, multidisciplinary DFU

Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients: Evidence from a Hospital-Based Study in Rajshahi, Bangladesh

Summary: This 2026 cross-sectional study of 159 type 2 diabetes patients with foot ulcers at Rajshahi Diabetic Association General Hospital (Bangladesh) found that 63.5% had severe DFU (Wagner grades 3–5). Severe cases showed higher rates of peripheral arterial disease (PAD), peripheral neuropathy (PN), poor glycemic control, prior amputation, longer ulcer duration, and greater treatment costs. Firth’s penalized logistic regression identified independent predictors: older age, poor glycemic control, PN, PAD, and prior amputation. The predictive model demonstrated strong performance (AUC 0.924, accuracy 85.5%). Findings underscore the need for early screening and aggressive management of modifiable risk factors to prevent progression to severe ulcers and reduce amputation risk in resource-limited settings.

Key Highlights:

• 63.5% of DFU cases were severe (Wagner 3–5); higher costs and complications in severe group
• Independent risk factors: older age (aOR 1.08), poor glycemic control (aOR 3.90), PN (aOR 3.41), PAD (aOR 7.54), prior amputation (aOR 13.67)
• Strong model performance with good calibration and clinical utility
• Authors: Shah Tanzen Jahan, Durga H. Kutal, Anicha Akter, Md. Selim Reza, Md. Kabirul Islam, Md. Monimul Huq

Read full article (open access)

Keywords: diabetic foot ulcer severity, risk factors DFU, peripheral neuropathy, peripheral arterial disease, Shah Tanzen Jahan

🔬 Spotlight: From Molecules to Populations — Bridging Mechanistic and Clinical Insights in Diabetic Wound Healing

Summary: Two recent publications highlight the full spectrum of diabetic wound research — from benchside mechanistic biology to population-level risk analysis. Together, they show how molecular targets and systemic biomarkers may eventually intersect to shape precision strategies for preventing and treating diabetic foot complications.

1. Molecular Focus — METTL3/GDF11 Pathway in Socket Healing

A study published in Diabetes, Metabolic Syndrome and Obesity explored how METTL3-mediated m6A modification regulates GDF11 expression, promoting extraction socket healing in diabetic rat models. Researchers demonstrated that overexpression of METTL3 improved trabecular bone formation, enhanced soft tissue healing, and restored angiogenesis. Mechanistically, the pathway hinges on stabilizing GDF11 transcripts via m6A methylation. When GDF11 was knocked down, much of METTL3’s benefit was reversed, underscoring this axis as a potential therapeutic target.

Notably, the use of micro-CT, histology, and gene expression assays confirmed both structural and molecular benefits. The translational implication is clear: modulating RNA methylation machinery could one day enhance oral and cutaneous wound repair in patients with diabetes, moving beyond symptomatic care toward biomaterial or gene-based interventions.

2. Population Focus — Inflammation and Nutrition Biomarkers in DFU Risk

In contrast, a large combined cross-sectional and retrospective study in Frontiers in Endocrinology examined over 31,000 NHANES participants plus clinical cohorts. The analysis revealed that composite indices linking inflammation and nutrition — such as the neutrophil-albumin ratio (NAR), monocyte-albumin ratio (MAR), red cell distribution width-albumin ratio (RAR), as well as the hemoglobin-albumin-lymphocyte-platelet (HALP) score and Prognostic Nutritional Index (PNI) — strongly associate with diabetic foot ulcer (DFU) prevalence.

High inflammatory ratios predicted greater odds of DFU, while better nutritional scores (HALP, PNI) were protective. These findings confirm what clinicians often see anecdotally: systemic inflammatory load and malnutrition compromise tissue repair, making individuals more vulnerable to chronic ulcers.

3. Connecting the Dots — Why Both Levels Matter

When viewed together, these studies illustrate the multi-layered nature of diabetic wound pathology. At the molecular level, disrupted post-transcriptional regulation (METTL3/GDF11) impairs local tissue repair. At the population level, imbalances in systemic inflammation and nutrition further compound risk. This dual perspective suggests that the future of diabetic wound care will not rest on one approach alone. Instead, clinicians may soon combine:

• Molecular therapies — agents or biomaterials designed to enhance beneficial RNA modifications, boost angiogenesis, or support cellular repair pathways.
• Risk stratification tools — composite blood indices (e.g., NAR, HALP, PNI) integrated into screening protocols to identify high-risk patients earlier.
• Personalized care pathways — tailoring wound interventions not just by ulcer stage and location, but also by underlying molecular signatures and systemic biomarker profiles.

This convergence could redefine how diabetic wounds are prevented and treated: precision medicine approaches at the molecular level, layered onto predictive analytics at the population level.

Clinical Takeaway

For wound care teams, the practical message is twofold: support robust systemic health (nutrition, inflammation control) while staying attuned to emerging molecular targets like METTL3/GDF11 that may soon influence therapeutic options. By bridging scales — from gene regulation to bedside biomarkers — the field is moving toward a more holistic, integrated model of diabetic wound care.

Further Reading:

• METTL3/GDF11 Mechanistic Study
• Biomarker Study in Frontiers in Endocrinology

Keywords:
diabetic foot ulcers,
METTL3,
GDF11,
inflammation biomarkers,
nutritional indices,
precision medicine

A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

Summary: This narrative review synthesizes DFU’s complex etiology, affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, neuropathy, hyperglycemia-induced immune defects, and biofilms. It covers diagnostic tools (TCOM, ABI, biopsy) and therapies from offloading/compression to advanced options like growth factors, stem cells, and bioengineered skins (50-70% closure rates). Microbial dysbiosis (e.g., Staphylococcus dominance) exacerbates inflammation; the review calls for personalized, multidisciplinary approaches with AI diagnostics and nanotech antimicrobials to reduce global burden and enhance limb salvage.

Key Highlights:

• Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection.
• Immune Dysbiosis: Hyperglycemia shifts macrophages to M1; biofilms (Staph/Pseudomonas) resist antibiotics.
• Therapies: Offloading (TCCs 80% efficacy); HBOT (50% closure); bioengineered skins (70% in RCTs).
• Future: AI for risk prediction; nanotech for targeted delivery; microbiome modulation.
• Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading.

Read full article

Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins

Continuous Glucose Monitoring and Diabetic Foot Ulcers: Is it Time to Walk in Range? A Brief Narrative Review

Summary: 2026 brief narrative review summarizes evidence on continuous glucose monitoring (CGM) in diabetic foot ulcer (DFU) management. Both hypo- and hyperglycemia delay healing and raise mortality; CGM outperforms self-monitoring for control. Emerging data indicate CGM-derived metrics like time in range (TIR) may promote wound healing by stabilizing glucose, reducing complications. Positions CGM as promising for DFU outcomes and amputation prevention, but notes need for well-designed trials to confirm benefits and inform clinical guidelines.

Key Highlights:

• Evidence: CGM enhances control; glucose extremes impair repair.
• Potential: TIR optimization for healing acceleration.
• Call: Trials needed for everyday use in DFU care.
• Relevance: Complements prevention (AI screening) and advanced therapies by addressing systemic glycemic factors in hard-to-heal DFUs.

Read full review (subscription may be required)

Keywords: continuous glucose monitoring, DFU management, time in range, glycemic control

Wound Care Practitioners Should Screen Patients for Sleep Apnea—Here’s How!

Summary: In a reflective blog post on her site, **Caroline Fife, M.D.**, highlights the under-recognized role of obstructive sleep apnea (OSA) in delayed wound healing. She shares personal insight and clinical observations suggesting that leg edema, forgetfulness, and poor healing may be rooted in undiagnosed OSA—and urges wound care clinicians to proactively screen using the simple General Practice Sleep Scale (GPSS).

Key Highlights:

• Sleep apnea may contribute to systemic issues (edema, poor wound repair, cognitive decline) that impede healing.
• Patients frequently dismiss OSA symptoms as “normal aging”—practitioners can bridge that gap with targeted screening.
• The GPSS offers a quick and effective tool to triage OSA risk, improving detection during routine visits.
• Clinicians treating non-healing wounds should consider whether addressing systemic sleep disorders could transform outcomes.

Read the full blog post on CarolineFifeMD.com

Keywords:
sleep apnea,
wound healing,
leg edema,
GPSS (General Practice Sleep Scale),
screening tools,
Caroline Fife

America’s Amputation Crisis: The Path Forward to Save Limbs and Lives

Summary: This final installment in a four-part series on America’s preventable amputation crisis emphasizes systemic solutions to combat unnecessary limb loss, especially in patients with peripheral artery disease (PAD) and diabetes. It critiques healthcare incentives favoring amputation over preservation and proposes a comprehensive approach including early PAD screening via the Ankle-Brachial Index (ABI) test, clinician education, supervised exercise therapy (SET), insurance reforms for limb-salvage procedures, and addressing disparities to enhance wound care outcomes and reduce amputation rates.

Key Highlights:

• The Amputation Reduction and Compassion (ARC) Act seeks to mandate PAD screening coverage under Medicare and Medicaid, with state-level advances like Illinois’ 2025 insurance mandate for at-risk groups.
• Supervised exercise therapy (SET) promotes collateral vessel growth to improve circulation, but low completion rates (only 5%) highlight needs for accessible programs like the Global PAD Association’s “My Steps” initiative achieving 75% retention.
• Insurance barriers delay limb-salvage interventions; reforms call for specialist peer reviews and adherence to Society for Vascular Surgery guidelines before approving amputations.
• Addressing disparities in Black communities and the “amputation belt” involves building centers of excellence, telemedicine, and equity audits to cut amputation rates by up to 87% in underserved areas.
• Innovations like deep vein arterialization (DVA) require expedited coverage via Coverage with Evidence Development to support complex wound healing in critical limb-threatening ischemia (CLI).

Read full article

Keywords:
peripheral artery disease,
limb salvage,
supervised exercise therapy,
amputation prevention,
diabetic foot care

PGIMER Marks World Diabetes Day with Special Patient Awareness Programme

Summary: On World Diabetes Day 2025, PGIMER Chandigarh hosted an awareness program for 100+ patients, focusing on diabetic foot ulcers (DFUs) as a major complication. Experts like Dr. Prabhat Rijal discussed hypoglycemia risks and DFU prevention through daily foot checks, proper footwear, and HbA1c <7%. The event highlighted multidisciplinary care (endocrinologists, surgeons, podiatrists) to reduce 15-25% DFU incidence and 20% amputation rate, with calls for community screening to address India's 77M diabetics.

Key Highlights:

• DFU Risks: Neuropathy/circulation issues cause 15-25% incidence; 50% recur without care.
• Prevention: Daily inspections, offloading, glycemic control; early referral cuts amputations 50%.
• Event: 100+ attendees; sessions on hypoglycemia, DFU management; free screenings.
• Expert: Dr. Rijal: “DFUs from poor sensation/healing; education saves limbs.”
• Impact: Targets India’s 77M diabetics; promotes MDT for 80% 6-week healing.

Read full article

Keywords: World Diabetes Day, diabetic foot ulcers, PGIMER, amputation prevention, patient education

Complications of Diabetes Mellitus: Foot Ulcer

Summary: This article details a clinical case of a 58-year-old man with type 2 diabetes who developed a right great toe ulcer from ill-fitting shoes, progressing to deep infection, osteomyelitis, and below-knee amputation due to delayed recognition amid neuropathy and vascular issues. It underscores the high prevalence of diabetic foot ulcers (DFUs)—affecting 15% of diabetics lifetime, with 14-24% risking amputation—and the critical need for routine screening, offloading, and aggressive debridement. Expert insights highlight monofilament testing for sensory loss and MRI for bone involvement, advocating multidisciplinary approaches to prevent progression from minor wounds to life-altering complications in wound care.

Key Highlights:

• Case details: Ulcer started as a callus from pressure; neuropathy masked pain, allowing infection spread to bone, requiring antibiotics, debridement, and eventual amputation after failed revascularization.
• Prevalence stats: DFUs occur in 15% of diabetics; 25% of moderate-severe cases lead to amputation; annual U.S. cost exceeds $9 billion.
• Symptoms and risks: Painless ulcers from sensory loss; vascular insufficiency delays healing; common in males over 40 with >10 years diabetes.
• Diagnosis: Semmes-Weinstein monofilament for neuropathy; probe-to-bone test (positive in 66% with osteomyelitis); MRI differentiates infection from Charcot.
• Prevention/treatment: Daily foot checks, proper footwear, glycemic control; offloading casts, hyperbaric oxygen, and vascular surgery for salvage.

Read full article

Keywords: diabetic foot ulcer, neuropathy, osteomyelitis, amputation prevention, monofilament testing

Diabetic Foot Disease: Current Challenges, Emerging Concepts and Future Directions

Summary: This open MDPI Topic Collection highlights diabetic foot disease as a major diabetes complication, with 19–34% lifetime risk of foot ulcers and 9–26 million new cases annually worldwide. It leads to lower-limb amputations, reduced quality of life, high healthcare costs, and mortality rates comparable to many cancers. While much research focuses on acute ulcer and infection management, significant gaps remain in prevention, recurrence, long-term outcomes, multidisciplinary care models, health economics, and implementation science. The collection welcomes submissions on innovative diagnostics, prevention strategies, patient-centered care, and emerging paradigms to improve outcomes and sustainability of diabetic foot care systems.

Key Highlights:

• Emphasizes prevention and long-term management beyond acute care
• Calls for multidisciplinary approaches and implementation research
• Addresses global burden including high amputation and recurrence rates
• Open for submissions on diagnostics, economics, and novel therapies

View topic collection

Keywords: diabetic foot disease, DFU prevention, multidisciplinary foot care

Predicting Diabetic Neuropathy: ML Model for Early Detection in T2DM

Summary: This retrospective study analyzes data from 1,001 T2DM patients in Xinjiang, China, to build and validate machine learning models for diagnosing diabetic peripheral neuropathy (DPN), a key precursor to foot ulcers and amputations. Using SVM-RFE and LASSO, seven risk factors (age, diabetes duration, 2hPG, LDL-C, blood urea, eGFR, urinary uric acid) were identified. The Random Forest model excelled with an external validation AUC of 0.953, supporting precision screening in high-risk regions to mitigate wound complications through timely interventions.

Key Highlights:

• Random Forest model achieved top performance (training AUC 1.000, external AUC 0.953), outperforming GBM, GLM, and SVM for DPN prediction.
• Key risks include age (≥50 years elevates odds), prolonged diabetes duration, and renal markers like reduced eGFR, linking to neuropathy progression.
• External validation on 123 patients confirmed accuracy (86.3%), sensitivity (93.0%), and no overfitting via bootstrapping and calibration.
• Model addresses Xinjiang’s high DPN prevalence, enabling early detection to prevent painless ulcers and non-traumatic amputations in T2DM.
• Limitations: Single-center data; future needs include multicenter trials and integration of genetic/dietary factors for broader applicability.

Read full article

Keywords:
diabetic peripheral neuropathy,
DPN prediction,
machine learning diabetes,
T2DM complications,
foot ulcer prevention

Natural Bioactive-Based Advanced Wound Dressings for Diabetic Wound Healing: A Systematic Review of Emerging Biomaterial Platforms

Summary: This PRISMA-guided systematic review analyzed 14 studies on natural bioactive-incorporated advanced dressings for diabetic wounds. Hydrogels, hydrocolloids, nanofibers, and hybrid systems loaded with curcumin, propolis, berberine, and plant extracts demonstrated strong antimicrobial, anti-inflammatory, antioxidant, and pro-angiogenic effects via modulation of NF-κB, VEGF, and TGF-β pathways.

Key Highlights:

• 14 studies included after screening 5256 records
• Key bioactives: curcumin, propolis, bee venom, plant extracts
• Mechanisms: reduced inflammation/oxidative stress + enhanced angiogenesis
• Hydrogels and nanosystems showed highest translational potential

Read full open-access review

Keywords: natural bioactive wound dressings, diabetic wound hydrogel, curcumin wound, Fahrurroji A, Suhandi C

Predicting Success in Spinal Cord Stimulation for the Diabetic Foot: The Role of Infrared Thermography

Summary: This study (Bao et al., 2025) explored whether perioperative infrared thermography (IRT) can predict which patients with diabetic foot complications benefit most from spinal cord stimulation (SCS). Findings suggest that small changes in limb skin temperature after surgery may forecast long-term success in limb salvage.

Key Highlights:

• Study cohort: 33 patients with diabetic foot complications underwent SCS.
• Temperature changes: Patients whose skin temperature rose by ≥ –0.12 °C within one week of surgery achieved higher limb salvage rates.
• Limb salvage outcomes: Overall, 78.8% of limbs treated with SCS avoided amputation.
• Neuropathy factor: Success rate was lower in those with large-fiber neuropathy (59.1%) compared to patients without neuropathy (88.6%).
• Ulcer grade: Severity of ulceration did not significantly predict outcomes.
• Clinical significance: IRT offers a low-cost, non-invasive tool to identify patients most likely to benefit from SCS, improving patient selection and treatment planning.

Read the full article on Diabetic Foot Online

Keywords:
Bao,
spinal cord stimulation,
infrared thermography,
diabetic foot,
limb salvage

Heel Diabetic Foot Osteomyelitis: A Current Challenge in the Clinical Practice

Summary: This retrospective observational study assessed outcomes of patients with diabetic foot osteomyelitis (DFO) managed in a specialized diabetic foot service between 2019 and 2022. Researchers compared patients with heel DFO to those with forefoot or midfoot DFO over a one-year follow-up, examining healing rates, healing time, amputation, and mortality.

Findings: Among 114 patients (mean age 67.9 years, 72.8% male, 91.2% type 2 diabetes), 30 had heel DFO and 84 had forefoot/midfoot DFO. Heel DFO patients exhibited more severe infection indicators, including larger ulcers (>5 cm), higher C-reactive protein levels, and greater prevalence of gangrene and peripheral arterial disease (PAD). Healing outcomes were significantly poorer for heel DFO cases, with longer healing times and higher rates of major amputation.

• Healing rate: 66.7% (heel) vs 97% (forefoot/midfoot)
• Healing time: 14 ± 6 weeks (heel) vs 6.8 ± 5 weeks (forefoot/midfoot)
• Major amputation: 10% (heel) vs 0% (forefoot/midfoot)
• Mortality: 6.6% (heel) vs 4.8% (forefoot/midfoot)

Multivariate analysis identified heel DFO and PAD as independent predictors of major amputation and non-healing. The study concludes that heel DFO represents a distinct clinical challenge associated with worse prognosis and slower recovery compared to other DFO sites.

Read full article

Keywords:
diabetic foot osteomyelitis,
heel ulcer,
diabetic foot ulcer,
amputation risk,
peripheral arterial disease

Development and Validation of a Diagnostic Nomogram for Wagner Grade ≥2 Diabetic Foot Ulcers in Patients with Diabetic Kidney Disease

Summary: Researchers developed and validated a practical nomogram to predict the risk of moderate-to-severe (Wagner grade ≥2) diabetic foot ulcers in patients with diabetic kidney disease (DKD). The model incorporates readily available admission parameters such as white blood cell count, hemoglobin, albumin, HbA1c, and clinical factors (hypertension, CAD, BMI). It demonstrates good discriminatory ability and calibration, providing clinicians with a bedside tool for early identification of high-risk patients. Early risk stratification can guide intensified preventive foot care, offloading, vascular assessment, and multidisciplinary intervention to reduce progression to severe ulcers, infection, and amputation.

Key Highlights:

• Nomogram based on routine labs and comorbidities for Wagner ≥2 DFU prediction in DKD patients
• Supports early risk stratification and targeted prevention
• Addresses high amputation risk in combined diabetes + kidney disease population

Read full open-access article

Keywords: diabetic foot ulcer nomogram, Wagner grade DFU, diabetic kidney disease

High TEWL Predicts Diabetic Foot Ulcer Recurrence

Summary: A multicenter observational study led by the NIDDK Diabetic Foot Consortium (Sen et al., 2025) reveals that high transepidermal water loss (TEWL) at the site of closed a diabetic foot ulcer (DFU) significantly increases the risk of recurrence within 16 weeks. Using a handheld evaporimeter, researchers measured TEWL at the healed DFU and compared it to a reference site on the opposite foot.

Key Findings:

• Among 418 patients tracked up to 16 weeks post-closure, 21.5% experienced recurrence.
• A TEWL threshold of >30 g/m²/h marked a high-risk group—35% recurrence compared to 17% in the low-TEWL group (OR 2.66; p < 0.001). Self-reported recurrence strongly aligned with clinician assessments.
• This study suggests that visual wound healing alone may not reflect true functional barrier restoration—defined as “invisible wound” when TEWL remains high despite closure.

Implications: Measuring TEWL post-closure may serve as a valuable biomarker to differentiate between visually healed wounds and those at risk of reopening—enabling clinicians to tailor surveillance and interventions to improve long-term outcomes and prevent relapse.

Read the full Medscape commentary

Keywords: transepidermal water loss, diabetic foot ulcer recurrence, invisible wound, Chandan K. Sen, skin barrier function

Dosing Walking Like a Drug: An AI Chatbot for Diabetic Foot Remission Following Limb Reconstruction

Summary: This protocol paper outlines a conversational AI chatbot designed to guide diabetic foot remission after wound healing or limb reconstruction by treating walking and therapeutic footwear as titratable “drugs.” The system integrates daily data (step counts via phone/wearable, paired foot skin temperature differences, shoe wear time, and symptom checks) to assign risk tiers (green/amber/red) and deliver personalized next-day guidance. Activity advances gradually (~500 steps/week) while gated by thermometry (hold/reduce if ≥2.2°C side-to-side difference). Footwear progression starts conservatively and escalates only with stable skin checks. Built on prior SmartBoot sensor work, the single-arm feasibility pilot (n=30) will assess engagement, safety, and implementation before larger trials. The approach aims to bridge the high-relapse gap (up to 40% within a year) through structured, data-driven home monitoring.

Key Highlights:

• AI chatbot titrates walking (~500 steps weekly increments) and footwear based on real-time thermometry and sensors
• 2.2°C temperature difference threshold triggers de-escalation and clinical escalation if persistent
• Addresses 40% recurrence risk with precise, responsive remission guidance
• Authors/key contributors: Lucian Feraru, David Klonoff, Bijan Najafi et al.

Read full protocol article

Keywords: AI chatbot diabetic foot, diabetic foot remission, walking dosing, Bijan Najafi

Medial Arterial Calcification & Diabetic Foot Ulcer Management

Summary: Recent literature recognizes medial arterial calcification (MAC) in diabetic foot ulcer (DFU) patients, especially those with diabetic kidney disease (DKD), as more than a background finding—it’s now seen as a strong predictor of major amputation risk. Standard vascular assessment tools like the ankle-brachial index (ABI) are often unreliable in the presence of MAC, which makes imaging/radiographic scoring and clinical classification essential adjuncts.

Key Highlights:

• Risk factor quantification: In DKD stages 3b-5, severe MAC (versus no MAC) confers ~4.5× greater odds of major amputation after adjusting for ulcer location and grade.
• Ulcer location & grade matter: Ulcers in the mid- or hindfoot and higher Texas grades (2-3) also independently predict worse outcomes.
• Limitations of ABI: Calcified arteries often render ABI readings unreliable; MAC should be considered as an alternative or adjunct measure.
• Possible protective factor: Use of antiplatelet agents showed a trend toward lower major amputation risk, though results were borderline statistically.
• Ease of detection: MAC scoring via foot radiographs is feasible and may be adopted in clinical practice to improve risk stratification.

Read the full letter/editorial on HMP Global Learning Network

Keywords:
medial arterial calcification,
diabetic foot ulcer,
diabetic kidney disease (DKD),
amputation risk,
ulcer location,
antiplatelet therapy

Incidence of diabetic foot ulcer and its predictors among adult diabetes patients in Northern Ethiopia: a retrospective cohort study

Summary: This retrospective cohort study assessed the incidence and key predictors of diabetic foot ulcers among adult diabetes patients in Northern Ethiopia. Following 321 individuals over several years, the research identified clinical and demographic factors significantly associated with ulcer development, emphasizing the importance of early detection and targeted prevention for high-risk patients.

Key Highlights:

• The incidence rate of diabetic foot ulcers was 1.01 per 100 person-years, with 11.8% of patients developing ulcers during follow-up.
• Older age (≥70 years) increased the risk nearly fifteenfold compared with younger patients.
• Other predictors included rural residence, hypertension, neuropathy, obesity, and abnormal HDL cholesterol levels.
• Findings underscore the need for proactive risk-based management in diabetic populations.

Read full article

Keywords: diabetic foot ulcer, incidence, predictors, retrospective cohort, Ethiopia

Development and validation of a nomogram for predicting moderate-to-severe diabetic foot ulcers in type 2 diabetes

Summary: This study developed and validated a nomogram model to predict the risk of moderate to severe diabetic foot ulcers (DFUs) in patients with type 2 diabetes. Using retrospective data from 499 hospitalized patients, the authors identified 9 independent predictors and demonstrated that their model had excellent discrimination, calibration, and clinical utility.

Key Highlights:

• Study cohort: 499 patients with type 2 diabetes hospitalized between January 2021 and December 2023.
• Predictors included: Diabetic kidney disease (DKD), diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), peripheral angiopathy (PAD), D-dimer, K-time, total cholesterol (TC), LDL-C, and HDL-C.
• Model performance: The nomogram achieved an AUC of 0.977 (95% CI 0.965–0.989) in the training set and 0.977 (95% CI 0.958–0.996) in the validation set.
• Calibration & validation: Calibration curves showed strong agreement between predicted and observed outcomes. Decision curve and clinical impact analyses supported its clinical usefulness.
• Novel biomarkers: Inclusion of coagulation markers (K-time and D-dimer) with microvascular and lipid metrics enhances predictive capability.
• Implications: The nomogram can guide early identification of high-risk patients, enabling preventive strategies to reduce ulcer progression and limb loss.

Read the full article in Frontiers in Endocrinology

Keywords:
Jinying Zhang,
Jing Lin,
Lizhen Wu,
Jiayu Lin,
nomogram,
diabetic foot ulcer prediction,
type 2 diabetes,
coagulation markers,
DKD,
DPN,
PAD

Charcot’s Legacy in Cast and Canvas: Visual Healing in Modern Diabetic Foot Care

Summary: This letter to the editor in The International Journal of Lower Extremity Wounds reflects on how Jean-Martin Charcot’s fusion of medicine and art still shapes contemporary diabetic foot care. Charcot’s visual pedagogy—sketches, casts, and sculptures (often in collaboration with physician-artist Paul Richer)—helped clinicians “see what others overlook,” linking bedside observation with anatomical understanding. The author argues that this visual tradition endures today through photography, advanced imaging, and creative self-expression in care.

Key Points:

• Visual communication as therapy: Creative expression (drawing, color, symbols) can provide patients with Charcot foot a language for vulnerability, offering psychological relief and reinforcing the therapeutic potential of art.
• Patient voice and psychosocial burden: Qualitative narratives (e.g., work cited by Jody Lucas) describe immobilization, pain, isolation, and even suicidality; patients report restricted mobility, employment disruption, and strained family roles during long casting periods.
• Holistic, empathetic care: The piece calls for integrated models that address both biomechanical needs (e.g., total contact casting) and psychosocial dimensions—validating lived experience, promoting connection, and using visuals to bridge clinician-patient understanding.
• Modern echoes of Charcot: While tools have evolved from plaster casts to digital imaging, the clinician’s role as careful observer and interpreter remains central to patient-centered diabetic foot care.

Read the article at SAGE Journals

Keywords:
Jean-Martin Charcot,
Paul Richer,
Jody Lucas,
Charcot foot,
visual healing,
total contact cast,
patient-centered care,
art therapy in medicine

Characteristics of Diabetic Foot Ulcer Patients

Summary: This clinical study is designed to describe the demographic, clinical, and laboratory features of patients living with diabetic foot ulcers (DFUs). By analyzing data from approximately 200 participants, the trial seeks to better understand the patient population and inform future strategies for prognosis and treatment.

Key Details:

• Study type: Cross-sectional, descriptive-analytical study.
• Participants: About 200 adult patients diagnosed with diabetic foot ulcers.
• Data collection: Demographics, ulcer characteristics (size, duration, grade), associated comorbidities, and laboratory parameters.
• Status: Currently recruiting.
• Objective: To generate a clearer clinical and laboratory profile of DFU patients, supporting improved risk stratification and therapeutic planning.

View the full study record on ClinicalTrials.gov

Keywords:
diabetic foot ulcer,
patient characteristics,
comorbidities,
laboratory data,
clinical study

Home-Based Exercise to Improve Functional Outcomes in Veterans With a Recently Healed Diabetic Foot Ulcer: Protocol for a Pilot Randomized Controlled Trial

Summary: This pilot randomized controlled trial will evaluate the feasibility and acceptability of a 12-week home-based exercise program designed for veterans aged 50 and older with recently healed diabetic foot ulcers. The study aims to address mobility loss caused by prolonged off-loading treatment, with the goal of improving lower extremity strength, tissue perfusion, glycemic control, and overall function.

Key Highlights:

• Background: Diabetic foot ulcers often result in reduced mobility due to off-loading treatments. Regaining mobility is essential to glycemic control, vascular health, and independence, yet there is little research on exercise during ulcer remission.
• Study design: 25 veterans will be randomized (3:1 ratio) to either the home-based exercise program or standard care.
• Intervention: Internet-based videoconference classes twice weekly plus home cycling three times per week.
• Control: Standard-of-care guidance without structured exercise intervention.
• Outcome measures: Feasibility, acceptability, gait speed, knee extension strength, cutaneous perfusion, community mobility, and physical activity levels.
• Status: Funded in July 2024; data collection runs October 2024–March 2026. As of June 2025, 12 participants enrolled and 6 randomized. Recruitment continues through December 2025.
• Next steps: If feasible and acceptable, this protocol will lead to a larger multisite trial examining impacts on mobility, cardiovascular outcomes, and ulcer recurrence.

Read the full article in JMIR Research Protocols

Keywords:
diabetic foot ulcer,
home-based exercise,
veterans health,
mobility outcomes,
rehabilitation,
randomized controlled trial

Efficacy of Extracorporeal Shockwave Therapy in the Management of Chronic Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis

Summary: This systematic review and meta-analysis assessed eight randomized controlled trials involving 672 patients, comparing extracorporeal shockwave therapies (ESWT) plus standard care versus standard care alone for diabetic foot ulcers. The authors found that ESWT significantly improves complete ulcer healing rates (OR = 2.747, p < 0.01) with low heterogeneity (I² = 0.02).

Key Highlights:

• Healing benefit: ESWT combined with standard care showed significantly higher rates of complete ulcer healing compared to standard care alone.
• Statistical strength: Low heterogeneity suggests consistency across included trials.
• Adjunct therapy role: ESWT may be a valuable adjunct to standard wound care protocols for chronic diabetic foot ulcers.
• Future need: Additional high-quality trials with standardized protocols are needed to confirm optimal dosing, timing, and patient selection.

Read the full article in Medical Sciences

Keywords:
Ruiz-Muñoz, M.,
Rueda-Zapata, L.,
Martinez-Barrios, F.-J.,
Nováková, T.,
Lopezosa-Reca, E.,
Gonzalez-Sanchez, M.,
Fernandez-Torres, R.,
Galan-Mercant, A.,
extracorporeal shockwave therapy,
diabetic foot ulcer,
meta-analysis

Smart Grey Wolf neural network (MGWONET): transforming diabetic foot ulcer analysis

Summary: This article presents the MGWONET model, an advanced neural network based on the Grey Wolf Optimizer algorithm, designed to enhance diabetic foot ulcer analysis and predict healing outcomes. The research outlines the model’s architecture, data integration methods, and validation process, demonstrating how artificial intelligence can improve wound assessment accuracy and support clinical decision-making.

Key Highlights:

• MGWONET applies Grey Wolf optimization to refine wound data interpretation.
• Achieves high accuracy in predicting diabetic foot ulcer healing outcomes.
• Facilitates early identification of non-healing wounds for timely intervention.
• Represents a step toward AI-driven diagnostic tools in wound care practice.

Read full article

Keywords: MGWONET, Grey Wolf Optimizer, artificial intelligence, diabetic foot ulcer, wound analysis

Nagaland University Researchers Find Plant Compound to Treat Diabetic Wound Foot Ulcers

Summary: Researchers at Nagaland University have identified sinapic acid, a naturally occurring antioxidant from edible plants, as a powerful therapeutic for accelerating wound healing in diabetic patients, particularly foot ulcers. Published in Nature Scientific Reports, the study demonstrates that oral administration of sinapic acid activates the SIRT1 pathway to promote tissue repair, angiogenesis, and inflammation control in preclinical models. Notably, a lower dose (20 mg/kg) proved more effective than higher doses (40 mg/kg), exhibiting an inverted dose-response curve. This discovery offers a safe, natural, and affordable alternative to synthetic drugs, potentially reducing amputation risks and improving accessibility in resource-limited settings, with pilot clinical trials planned next.

Key Highlights:

• Sinapic acid targets diabetic foot ulcers by addressing neuropathy, poor circulation, infections, and oxidative stress through SIRT1 activation.
• Preclinical results: Oral low-dose sinapic acid enhanced metabolic health, wound closure, and reduced side effects compared to higher doses.
• Global impact: Diabetes affects millions; delayed healing leads to ulcers and amputations—sinapic acid provides a non-invasive oral solution.
• Lead researcher: Prof. Pranav Kumar Prabhakar, Head of Biotechnology at Nagaland University, highlights limited efficacy of existing drugs.
• Future steps: Pilot trials to validate in humans, focusing on rural accessibility and patentable formulations.

Read full article

Keywords: sinapic acid, diabetic foot ulcers, SIRT1 activation, oral wound therapy, Nagaland University

Quality of Clinical Practice Guidelines for Diabetic Foot Management: A Systematic Review

Summary: This systematic review evaluates the methodological quality of clinical practice guidelines (CPGs) for diabetic foot ulcer (DFU) management using the AGREE II instrument. Multiple international and national guidelines were assessed across six domains (scope/purpose, stakeholder involvement, rigor of development, clarity, applicability, editorial independence). Results show significant variability: some guidelines score high in rigor and clarity, while others lack transparency in evidence synthesis, stakeholder input, or implementation strategies. Common weaknesses include limited patient involvement, outdated evidence, and poor applicability in resource-limited settings. Recommends development of higher-quality, regularly updated, and harmonized global guidelines to standardize care, reduce amputation rates, and improve outcomes in diabetic foot disease.

Key Highlights:

• AGREE II assessment reveals quality variability across DFU guidelines
• Strengths: Good scope and clarity in many documents
• Weaknesses: Inconsistent rigor, limited applicability, and patient input
• Call for updated, evidence-based, globally harmonized guidelines

Read full review

Keywords: DFU guidelines, AGREE II, diabetic foot management, clinical practice guidelines

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Summary: In this March 31, 2026 announcement, FibroBiologics, Inc. (Nasdaq: FBLG) reports successful completion of cGMP manufacturing for its investigational fibroblast-derived therapy CYWC628. The product is advancing to support a first-in-human Phase 1/2 clinical trial evaluating safety and efficacy in patients with refractory diabetic foot ulcers (DFUs). CYWC628 represents a novel regenerative approach leveraging fibroblasts to address the underlying deficits in chronic non-healing DFUs, a condition affecting up to 15–25% of people with diabetes and often leading to amputation. The milestone enables trial initiation in the first half of 2026 and underscores progress in cell-based therapies for hard-to-heal wounds.

Key Highlights:

• Successful cGMP manufacturing of CYWC628 completed
• Prepares for Phase 1/2 trial in refractory DFU patients
• Fibroblast-based regenerative platform targeting chronic wound deficits
• Addresses high unmet need in diabetic foot ulcer management

Read full announcement

Keywords: CYWC628, FibroBiologics, diabetic foot ulcer trial, fibroblast therapy

Pilot Study Could Improve Treatment of Chronic Diabetic Foot Ulcers

Summary: A recent pilot study suggests promising new strategies for treating chronic diabetic foot ulcers (DFUs), a condition that remains difficult to manage despite standard care. The research evaluates innovative interventions aimed at overcoming biological barriers such as impaired angiogenesis, persistent inflammation, and biofilm formation. Early results indicate potential for faster wound closure and reduced complication rates. While larger trials are needed, the findings highlight opportunities to expand the therapeutic toolbox for DFUs and improve limb salvage outcomes for patients with diabetes.

Key Highlights:

• Focuses on chronic, hard-to-heal diabetic foot ulcers
• Explores novel approaches targeting key healing barriers
• Early data shows potential for improved closure rates
• Addresses a critical gap in current DFU treatment options

Read full article

Keywords: diabetic foot ulcers, DFU pilot study, chronic wound treatment

Negative Pressure Wound Therapy for Complicated Diabetic Foot Wounds

Summary: This retrospective case series assesses negative pressure wound therapy (NPWT) in 30 diabetic patients with complicated foot or lower limb infections over 15 years. Following initial debridement and antibiotics, NPWT at -125 mmHg for 7-12 days promoted granulation and healing in 80% of cases, preventing major amputations despite high-risk features like ischemia and polymicrobial infections (e.g., MRSA, E. coli). Five patients (16.6%) required major amputations, and one died. No associations were found with standard classifications (WIFI, IWGDF, TPI). A literature review supports NPWT as an adjunct for faster healing and reduced amputations in selected DFUs, though guidelines caution its use in active infections. The study highlights NPWT’s potential in real-world settings but calls for larger RCTs to confirm benefits.

Key Highlights:

• NPWT achieved limb preservation in 80% of high-risk diabetic wounds, with 20% fully healing via grafts or sutures.
• Common pathogens like MRSA and E. coli were managed effectively post-debridement, reducing infection persistence.
• Average NPWT duration was 9 days, with hospital stays of 25 days, underscoring its feasibility in clinical practice.
• Challenges include guideline limitations for infected wounds and need for multidisciplinary approaches to optimize outcomes.
• Literature shows NPWT halves amputation risks compared to standard care in some trials, supporting its innovative role.

Read full article

Keywords:
diabetic foot ulcers,
negative pressure wound therapy,
wound healing innovations,
diabetic wound infections,
limb salvage in diabetes

Recent Advances in Nanozymes Toward Diabetic Foot Ulcers

Summary: 2026 narrative review covers recent advances in nanozymes for diabetic foot ulcers (DFUs). Nanozymes: Nanomaterials (metal oxides, carbon-based) mimicking enzymes (catalase, superoxide dismutase, peroxidase, glucose oxidase) with high stability, low cost, tunable activity. In DFUs: Counter hyperglycemia-induced oxidative stress (ROS scavenging), reduce infection (antibacterial), modulate inflammation, promote angiogenesis/collagen via ROS regulation. Examples: MnO2, CeO2, Pt-based nanozymes; glucose oxidase-like for hyperglycemic control. Advantages: Overcome natural enzyme limitations (instability, immunogenicity); synergistic with dressings (hydrogels, films). Preclinical evidence: Accelerated closure, better granulation in diabetic models. Challenges: Biocompatibility, long-term safety, clinical translation. Future: Smart/multi-functional nanozymes for personalized DFU therapy.

Key Highlights:

• Activity: ROS scavenging, antimicrobial, anti-inflammatory.
• Benefits: Stability, cost-effectiveness vs. natural enzymes.
• Applications: Topical delivery in DFUs.
• Relevance: Nano-synthetic enzyme mimics for chronic diabetic wounds.

Read full review

Keywords: nanozymes, diabetic foot ulcers, ROS scavenging, nano therapeutics

The Role of Gut Microbiota in Diabetic Foot Ulcer Healing: A Comprehensive Review

Summary: This 2026 comprehensive review explores the gut microbiota’s influence on diabetic foot ulcer (DFU) healing. Dysbiosis in type 2 diabetes patients alters short-chain fatty acid production, increases systemic inflammation (via LPS/endotoxemia), impairs immune response, and disrupts angiogenesis/collagen remodeling—key factors in chronic non-healing DFUs. Evidence from animal models and human studies links low microbial diversity to higher infection rates, prolonged inflammation, and amputation risk. Therapeutic modulation strategies: probiotics (Lactobacillus/Bifidobacterium), prebiotics, fecal microbiota transplantation (FMT), and diet interventions show promise in restoring balance, reducing oxidative stress, and accelerating healing. Calls for clinical trials to validate gut-targeted therapies as adjuncts in DFU management. Highlights the gut-skin axis as a novel target in diabetic wound care.

Key Highlights:

• Gut dysbiosis → systemic inflammation and delayed DFU repair
• Mechanisms: Reduced SCFAs, LPS translocation, immune dysregulation
• Potential therapies: Probiotics, FMT, dietary modulation
• Relevance: Gut microbiome as emerging target for chronic diabetic wounds

Read full review (open access)

Keywords: gut microbiota, diabetic foot ulcer, dysbiosis, probiotics, FMT

Diabetic Foot Ulcer Classification Models Using Artificial Intelligence and Machine Learning Techniques: Systematic Review

Summary: This systematic review examines the performance and limitations of machine learning (ML) models developed to classify and prognosticate diabetic foot ulcer (DFU) outcomes. The authors aggregated evidence from 13 papers across 11 studies, scrutinizing model variety, prediction accuracy, and methodological quality, and call for future work on externally validated and interpretable models.

Key Highlights:

• Scope: 11 studies (13 publications) were included, assessing ML models for outcomes such as wound healing, lower extremity amputation (LEA), and mortality.
• Model performance: Models reported area under the ROC curve (AUROC) values ranging from 0.56 to 0.94; many reached ≥0.8, indicating good discrimination.
• Bias & limitations: All examined studies had a high risk of bias due to inconsistent definitions, small sample sizes, and poor handling of missing data.
• Common predictors: Frequent variables included wound area, demographic factors, lab values, and foot-specific clinical features.
• Gaps identified: Few models underwent external validation or assessed calibration; most used opaque (non-explainable) algorithms, limiting clinical applicability.
• Future direction: The authors emphasize the need for ML models that are explainable, externally validated, and integrated into clinical workflows before deployment in DFU care.

Read the full review on JMIR

Keywords:
artificial intelligence,
machine learning,
diabetic foot ulcer,
classification models,
Manuel Alberto Silva,
Emma J Hamilton,
David A Russell,
Fran Game,
Sheila C Wang,
Sofia Baptista,
Matilde Monteiro-Soares

Use of Hypothermically Stored Amniotic Membrane on Diabetic Foot Ulcers: A Multicentre Retrospective Case Series

Summary: This retrospective multicentre study assessed the clinical outcomes of applying hypothermically stored amniotic membrane (HSAM) in chronic diabetic foot ulcers. Treatment led to faster epithelialization, improved granulation tissue, and reduced inflammation compared with standard care.

Key Highlights:

• Evaluated HSAM’s role in difficult-to-heal diabetic ulcers.
• Observed accelerated closure and reduced infection risk.
• Highlighted regenerative and anti-inflammatory effects.
• Supports HSAM as an adjunct in chronic wound management.

Read full article

Keywords:
amniotic membrane,
diabetic foot ulcer,
wound healing,
HSAM

Ethacridine Targets Bacterial Biofilms in Diabetic Foot Ulcers: Multi-Target Mechanisms

Summary: This study elucidates ethacridine’s antibacterial mechanisms in diabetic foot ulcers (DFUs) through integrated network pharmacology, molecular docking, molecular dynamics (MD) simulation, and clinical RT-qPCR validation. Identifying 105 overlapping targets, ethacridine modulates hub genes like AKT1 and MMP9, enriching in oxidative stress, inflammation, and bacterial response pathways (e.g., AGE–RAGE, TNF, IL-17). Docking confirmed strong MMP9 binding (−9.8 kcal/mol), with MD simulations verifying complex stability. In DFU patient tissues, RT-qPCR showed upregulated pro-healing genes (AKT1, HSP90AA1) and downregulated inflammatory/degradative ones (MMP9, MAPK8; p<0.0001). As a safe topical agent, ethacridine disrupts biofilms, mitigates inflammation, and fosters regeneration, offering a multi-functional approach to combat DFU infections and reduce amputations.

Key Highlights:

• Network analysis identified 105 common targets, with 10 hubs (e.g., AKT1, EGFR, MMP9) linked to oxidative stress, inflammation, and bacterial defense GO terms.
• KEGG pathways enriched in AGE–RAGE, TNF, and IL-17 signaling, underscoring ethacridine’s role in diabetic complications and biofilm disruption.
• Molecular docking: Binding energies < −5.0 kcal/mol, strongest for MMP9 (−9.8 kcal/mol); MD simulation: Stable complex (RMSD < 2.4 Å, ~2 H-bonds).
• RT-qPCR in 20 DFU patients: Upregulated AKT1/HSP90AA1 (p<0.0001) for survival/angiogenesis; downregulated MMP9/MAPK8 (p<0.0001) for matrix preservation and inflammation control.
• Implications: Topical ethacridine as affordable biofilm eradicator; future trials needed for resistance and efficacy in chronic wound management.

Read full article

Keywords: ethacridine, diabetic foot ulcers, bacterial biofilms, network pharmacology, molecular docking, Tianbo Li, Yuming Zhuang, Jiangning Wang

Early Clinical Experience with a Topical Desiccating Agent for Wound Bed Preparation in Diabetic Foot Ulcers

Summary: This retrospective case series evaluates the clinical outcomes of a novel topical desiccating agent (TDA) used under a compassionate-use protocol for wound bed preparation in 67 patients with hard-to-heal (chronic) diabetic foot ulcers (DFUs) treated between 2020 and 2023. The TDA, applied topically, facilitated effective debridement and promoted granulation tissue formation, leading to granulation in 88.1% of cases (mean time: 44.3 days) and complete re-epithelialization in 85.1% of patients. No adverse events were reported, and the agent was well-tolerated in this high-risk population, suggesting its potential as a safe, non-invasive adjunct to standard care. Further prospective studies are recommended to confirm these promising results.

Key Highlights:

• Patient cohort: 67 adults with chronic DFUs; treated under institutional ethics-approved compassionate-use protocol from 2020-2023.
• Granulation achievement: 88.1% of patients (mean time to granulation: 44.3 days), indicating rapid wound bed preparation.
• Healing outcomes: 85.1% reached complete re-epithelialization, highlighting TDA’s efficacy in promoting full closure.
• Safety profile: No adverse events reported; well-tolerated across all applications, suitable for high-risk diabetic populations.
• Implications: TDA offers a novel, clinic-applicable chemical debridement option; supports further evaluation in controlled trials for DFU management.

Read full article

Keywords: topical desiccating agent, diabetic foot ulcers, wound bed preparation, chemical debridement, granulation tissue, Johannes P Snels, Bart J Q van Luijk, Arjan C Assendelft

DAE Launches India’s First Nitric-Oxide Wound Dressing for Diabetic Foot Ulcers

Summary: The Department of Atomic Energy (DAE) launched ColoNoX, India’s first nitric-oxide (NO)-releasing wound dressing for diabetic foot ulcers (DFUs), developed by Bhabha Atomic Research Centre (BARC) and validated in Phase II/III trials. The DCGI-approved product enhances angiogenesis and antimicrobial action, accelerating healing in 70% of cases and reducing amputation risks by 40% in resource-limited settings. Affordable and locally produced, it addresses India’s 77M diabetics, with rollout via public-private partnerships for nationwide access.

Key Highlights:

• ColoNoX: NO from chitosan matrix promotes vascularization and kills bacteria without resistance.
• Trials: Phase II/III show 70% faster granulation; 40% amputation reduction vs standard dressings.
• Impact: Targets 15% DFU incidence; cost-effective for rural care.
• Launch: DAE/BARC initiative; partnerships for distribution.
• Quote: DAE Secretary: “Breakthrough for diabetic complications in India.”

Read full article

Keywords: nitric oxide dressing, diabetic foot ulcers, ColoNoX, BARC, amputation reduction

Preserving Limbs and Lives: The Role of Cellular, Acellular, and Matrix-like Products in Diabetic Foot Ulcer Care

Summary: This original research article in Wounds journal evaluates the clinical impact of cellular, acellular, and matrix-like products (CAMPs) in the management of diabetic foot ulcers (DFUs). DFUs represent a leading cause of nontraumatic lower extremity amputation, and standard-of-care alone achieves complete healing in fewer than one-third of patients at 12–20 weeks. CAMPs — encompassing living cellular constructs, decellularized dermal matrices, and extracellular matrix-based scaffolds — aim to restore the disrupted wound microenvironment by providing structural scaffolding, bioactive signals, and cellular mediators that chronic DFU wound beds lack. The study’s findings indicate that CAMP utilization is associated with reduced long-term lower-limb amputation risk and improved amputation-free survival, positioning these products as a critical component of limb preservation strategy in high-risk diabetic patients. The research adds to a growing body of evidence supporting CAMPs as more than wound dressings — they are active biological interventions in the limb salvage continuum.

Key Highlights:

• CAMPs associated with reduced long-term lower-limb amputation risk in DFU patients
• Improved amputation-free survival compared to standard care alone
• Encompasses full CAMP spectrum: cellular constructs, acellular matrices, ECM-based scaffolds
• Frames CAMPs as integral to limb preservation rather than adjunctive wound dressing
• Relevance: Timely given new 2026 CMS coverage and payment policies for cellular and tissue-based products (CTPs)

Read full study

Keywords: CAMPs, diabetic foot ulcer, limb preservation, acellular matrix, amputation prevention, cellular tissue products

The Role of Machine Learning in Infection Assessment of Diabetic Foot Ulcers: A Narrative Review

Summary: This 2026 narrative review critically evaluates machine learning (ML) applications for detecting infection in diabetic foot ulcers (DFUs), a major cause of hospitalization, amputation, and mortality in diabetes. Clinical assessment relies on subjective visual signs (redness, swelling, purulence), but inter-observer variability, atypical responses in neuropathy/ischemia, and poor documentation lead to delays or misdiagnosis. ML, especially deep learning on wound images, detects subtle infection features (erythema, exudate, necrosis, discoloration) with high accuracy. Covers image-based classification (infected vs. uninfected), tissue segmentation (necrotic vs. granulation), longitudinal monitoring, and prognostic models for healing/amputation risk. Highlights utility in telemedicine, remote monitoring, and resource-limited settings. Limitations: Image variability, dataset bias, lack of standardized protocols, limited prospective validation. Encourages ML as a supportive tool to complement clinical expertise, not replace it; calls for large-scale studies, regulatory approval, and workflow integration to reduce diagnostic errors and enable earlier intervention in DFIs.

Key Highlights:

• ML excels at image-based infection detection and classification (e.g., >90% accuracy in some models)
• Supports segmentation, monitoring, and prognosis in DFUs
• Benefits telemedicine and resource-limited care
• Limitations: Bias, variability, need for validation
• Relevance: Reduces subjectivity in chronic diabetic wound infection assessment

Read full article (open access)

Keywords: machine learning DFU, infection assessment, diabetic foot ulcer, telemedicine wound

Pilot Study Could Improve Treatment of Chronic Diabetic Foot Ulcers

Summary: A pilot study evaluated the GPP@ZnBG hydrogel—a self-regulating bioactive glass-embedded system—for chronic diabetic foot ulcers. The hydrogel dynamically responds to wound pH and glucose/oxidative stress: early alkaline conditions trigger controlled zinc ion release for antibacterial effects, while later degradation releases zinc, calcium, and silicate ions to promote angiogenesis and tissue repair. In the clinical pilot, treated ulcers showed a 94.57% relative reduction in wound surface area within 4 weeks. This active nanotechnology approach addresses persistent infection, inflammation, and impaired healing better than passive standard care and highlights pharmacists’ role in advanced product selection and patient education.

Key Highlights:

• 94.57% wound area reduction in 4 weeks for chronic DFU
• pH-responsive zinc delivery: antibacterial early, pro-angiogenic later
• Addresses biofilm, ROS, and poor perfusion in diabetic wounds
• Study authors: Zhao L, Chen S, Chen S, et al.

Read full article

Keywords: DFU hydrogel, bioactive glass wound care, chronic diabetic foot ulcer, zinc ion therapy

Horn-Shaped Perforator Flaps for Plantar Reconstruction in Diabetic Foot Ulcers

Summary: This review evaluates the use of horn-shaped perforator flaps for reconstructing plantar defects after debridement of diabetic foot ulcers. The technique provides like-with-like tissue (sensate, glabrous skin) with reliable blood supply from perforators, resulting in durable weight-bearing surfaces, reduced shear forces, and lower ulcer recurrence compared to skin grafts or free flaps. The authors discuss patient selection, surgical pearls, and outcomes in high-risk diabetic populations. It represents an important reconstructive option in limb salvage algorithms for deep plantar wounds.

Key Highlights:

• Horn-shaped design preserves sensation and provides robust plantar coverage
• Lower recurrence rates versus traditional grafting methods
• Useful in selected DFU cases after thorough debridement and vascular optimization

Read full open-access review

Keywords: perforator flap plantar, diabetic foot reconstruction, limb salvage flap

Diabetic Foot Care: New Tech & Preventing Amputations

Summary: With 1 in 5 diabetics facing foot ulcers and up to 20% leading to amputation (costing >$30,000/case), this article explores innovations like AI for early detection, bioengineered skin substitutes, hyperbaric oxygen therapy (HBOT), phage therapy, and telehealth to improve outcomes and accessibility. Emphasizing prevention through daily inspections, proper footwear, and glycemic control, it highlights tools like Podimetrics’ remote monitoring and community education to enhance adherence, ultimately reducing mobility loss and long-term healthcare burdens.

Key Highlights:

• Stats: 15% lifetime DFU risk; 25-33% amputation rate; $9B+ annual U.S. cost.
• AI Detection: Analyzes gait/genetics for risk prediction; Podimetrics uses images/patient data for proactive care.
• Wound Tech: Stem cells/platelet-rich plasma accelerate healing; bioengineered scaffolds support growth; HBOT boosts perfusion; phage targets resistant bacteria.
• Telehealth: Remote consults cut amputations (e.g., VA programs); challenges: equity, privacy.
• Prevention: Foot checks, smoking cessation, BMI control; peer support for adherence.

Read full article

Keywords: diabetic foot care, amputation prevention, AI prediction, phage therapy, telehealth wounds

The Impact of an Aggressive Clinic-Based Diabetic Foot Protocol: A Single-Center Case Series

Summary: In this July 2025 case series published in *Wounds*, Qing Jia, MD; Xiaojing Yin, MD; Wen Qin, MD; and Jiaojiao Bai, PhD report outcomes of implementing a four-step wound hygiene protocol for diabetic foot ulcers (DFUs) at a multidisciplinary clinic in Shanghai. Over 12 weeks, the team achieved an 80% complete healing rate in 20 patients, with the remainder showing significant improvement. Pain, exudate, and wound area all improved significantly (p < 0.001).

Protocol Details:

• Cleansing: Debridement and irrigation using povidone-iodine followed by saline.
• Debridement: Sharp removal of necrotic tissue 1–2 times weekly.
• Wound Edge Refashioning: Optimized margins to support healing.
• Dressing: Application of Aquacel Ag+ Extra antimicrobial dressing, capped with cotton gauze.

Outcomes: Mean wound area reduction was 95.1%, with a healing rate of 1.32 cm²/week. The average time to closure for healed wounds was 56.4 days. No serious adverse events were reported.

Conclusion: Applying a structured wound hygiene protocol in a clinic setting can produce rapid and robust healing in DFUs. To expand access, there’s a pressing need for widespread training and scalable care models.

🔗 Read the full case series on Wounds Journal

Keywords: wound hygiene protocol, diabetic foot ulcers, Qing Jia, Xiaojing Yin, Wen Qin, Jiaojiao Bai, wound cleansing, multidisciplinary clinic

Ischemia-Modified Albumin in Diabetic Foot Ulcers: Promising Marker or Incomplete Picture?

Summary: A letter by **Seshadri Reddy Varikasuvu, PhD** (AIIMS, Deoghar) published in *International Journal of Lower Extremity Wounds* (ahead of print, August 2025) critically examines a study by Juttada et al. that explored serial monitoring of ischemia-modified albumin (IMA) as a biomarker for healing in diabetic foot ulcers (DFUs).

Key Reflections:

• Varikasuvu acknowledges the novelty of using serial IMA measurements to reflect wound healing dynamics.
• However, he raises concerns about the study’s predictive validity, noting limitations such as inadequate adjustment for baseline albumin levels and neglect of oxidative therapies like hyperbaric oxygen therapy.
• The letter recommends that future biomarker research in DFUs should adopt a multi-marker strategy and account for oxidative stress variability to strengthen clinical utility.

Read the full letter in *International Journal of Lower Extremity Wounds*

Keywords:
ischemia-modified albumin (IMA),
diabetic foot ulcer,
biomarkers,
oxidative stress,
hyperbaric oxygen therapy,
wound healing monitoring

Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review

Summary: A narrative and systematic review published in Wound Repair & Regeneration (Sep–Oct 2025) by Fiona S. Gruzmark, Gabriela E. Beraja, Ivan Jozic, and Hadar A. Lev-Tov explores the emerging potential of systemic GLP-1 receptor agonists (commonly used in diabetes and weight loss) to support healing in diabetic foot ulcers (DFUs).

Key Highlights:

• DLRUs are a major global health burden—DFU incidence ranges from ~19% to 34%, with a 10% one-year mortality rate after ulcer diagnosis.
• GLP-1 receptor agonists have shown beneficial effects in related dermatologic conditions (e.g., alopecia, hidradenitis suppurativa), suggesting a broader regenerative or anti-inflammatory role.
• The review integrates narrative insights with a PRISMA-guided systematic search, noting potential reductions in DFU complications associated with GLP-1 use.
• This represents a promising therapeutic avenue—targeting multiple pathophysiologic domains (microvascular health, neuropathy, apoptosis, oxidative stress)—but requires clinical trials to confirm efficacy.

Read the full review in Wound Repair & Regeneration

Keywords:
GLP-1 agents,
diabetic foot ulcer,
systematic review,
narrative review,
wound healing
Fiona S. Gruzmark,
Gabriela E. Beraja,
Ivan Jozic,
Hadar A. Lev-Tov

Dehydrated Amnion-Chorion Membrane vs Standard of Care for Diabetic Foot Ulcers: A Randomized Controlled Trial

Summary: A prospective, multicentre RCT published in 2024 by **Shawn M. Cazzell**, **Joseph [last name?]**, **Robert D. D. [last name?]**, **OMA [initials?]**, and **M. L. Sabolinski** compared the efficacy of dehydrated amnion-chorion membrane (dACM) plus standard of care (SoC) versus SoC alone in treating complex diabetic foot ulcers (DFUs) extending into dermis, tendon, or bone, over 12 weeks.

Key Highlights:

• The dACM group had significantly higher closure rates at weeks 4 (12% vs 8%), 6 (22% vs 11%), 8 (31% vs 21%), 10 (42% vs 27%), and 12 (50% vs 35%).
• Patients in the dACM arm had a 48% greater probability of closure (hazard ratio 1.48; 95% CI: 0.95–2.29; p = 0.04).
• Median time to complete wound closure was 84 days with dACM, while half of the SoC group had not healed by week 12.
• The study population (218 patients total, 109 per arm) consisted of complex, chronic DFUs, demonstrating the trial’s real-world relevance.

Read the study abstract on PubMed

Keywords:
dACM,
dehydrated amnion-chorion membrane,
diabetic foot ulcer,
randomized controlled trial,
Shawn M. Cazzell,
M. L. Sabolinski

High Relapse Risk in Diabetic Foot Ulcers

Summary: A Medscape view article published in 2025 highlights striking new data showing that diabetic foot ulcers (DFUs) carry relapse risks at levels that match or exceed those of aggressive cancers. By pulling together recent studies on ulcer recurrence and limb preservation, the authors call for more vigilant follow-up and structured surveillance after remission.

Key Highlights:

• At 3 years after healing (remission), approximately **58%** of patients with DFUs experience recurrence.
• Similarly, about **50%** of patients who had chronic limb-threatening ischemia (CLTI) treated via endovascular intervention require reintervention within 3 years.
• Those relapse and reintervention rates are comparable to—or even higher than—those for many advanced cancers such as breast, colorectal, or prostate when considering a 3-year window.
• These findings underscore that “healed” DFUs should not be treated as endpoints but signals for ongoing risk; patients in remission need structured monitoring similar to post-cancer care protocols.

Read the full article on Medscape

Keywords:
diabetic foot ulcer recurrence,
chronic limb-threatening ischemia (CLTI),
relapse risk,
three-year rate

High Mortality & Amputation Rates After First Diabetic Foot Ulcer: CODIA Cohort Findings

Summary: A large cohort study from Greater Paris hospitals (August 2017-October 2023) examines the one-year outcomes in over 3,100 patients hospitalized with their first diabetic foot ulcer (DFU). The findings are alarming: ~21.6% died and ~24.2% underwent lower-limb amputation within 12 months. Key risk factors for death included older age, cardiac, hepatic or renal disease, cancer history, and systemic inflammation; amputation risk was linked to male sex, peripheral artery disease, admission through emergency, and markers of inflammation.

Key Highlights:

• Sample included 3,102 patients, median age ~70.7 years; 68% male.
• Cumulative incidence of death within 12 months: **21.64%**.
• Cumulative incidence of lower limb amputation within 12 months: **24.15%**.
• Strong predictors of mortality: chronic comorbidities (heart, liver, kidney), history of cancer, and elevated systemic inflammation.
• Key predictors of amputation: male gender, peripheral arterial disease, being admitted via the emergency department, and inflammation; interestingly, dementia was associated with *lower* risk of amputation.

Read the full article in Diabetes & Metabolism

Keywords:
first diabetic foot ulcer,
lower limb amputation,
one-year mortality,
peripheral artery disease,
systemic inflammation,
Julla Jean-Baptiste,
Théo Jolivet,
Candice Estellat,
Jean-François Gautier,
Florence Tubach

Association of Inflammation and Nutrition-Based Indicators With Diabetic Foot Ulcers

Summary: A new combined cross-sectional and retrospective study from China (Hua Chen, Yu Zhou, Jiezhi Dai) examines multiple inflammation and nutrition biomarkers and their association with prevalence of diabetic foot ulcers (DFUs). Using a large US dataset (NHANES) plus a clinical retrospective arm, the team finds strong links between DFU presence and indicators such as neutrophil-albumin, monocyte-albumin, red cell distribution width-albumin, HALP, and PNI.

Key Highlights:

• Data from ~31,126 participants in NHANES (1999–2004) and clinical data comparing DFU vs non-DFU patients.
• Higher tertiles of NAR, MAR, and RAR (ratios combining inflammatory cells or red-cell width with albumin) correlate with increased odds of DFU.
• Higher HALP (hemoglobin-albumin-lymphocyte-platelet) and Prognostic Nutritional Index (PNI) are inversely correlated with DFU – i.e. better nutrition/inflammation status associated with lower DFU risk.
• Non-linear relationships found, especially for RAR, showing risk climbs sharply at higher levels.

Read the full article in Frontiers in Endocrinology

Keywords:
inflammation biomarkers,
nutrition indices,
diabetic foot ulcer prevalence,
NHANES,
Hua Chen,
Yu Zhou,
Jiezhi Dai

Market Spotlight: North America’s Diabetic Foot Care Industry Poised for Strong Growth

Summary: According to a recent industry analysis, the diabetic foot ulcer (DFU) treatment market in North America was valued around **USD 1.27 billion** in 2024 and is projected to grow to about **USD 2.22 billion by 2034**, at a compound annual growth rate (CAGR) of roughly **5.74%**. The growth is being driven by rising diabetes prevalence, aging populations, innovation in biologics, devices, and increasing investment in homecare solutions.

Key Insights & Trends:

• Biologics’ dominance: Skin substitutes, stem cell therapies, and regenerative products are major contributors to current market value.
• Therapy Devices on the Rise: Advanced dressings, negative pressure wound therapy (NPWT), photobiomodulation, and newer device-based interventions (e.g. devices that release nitric oxide or detect infection) are expected to grow fastest.
• Homecare & Aging Demographics: As the population ages and more people are treated at home, demand for easy-to-use wound care products and preventive devices is increasing.
• Innovation & R&D Momentum: Research continues in diagnostics, monitoring technologies, smart dressings, and biologics to improve outcomes and cost-effectiveness.

Challenges & Considerations:

• Cost barriers—biologics and specialty devices remain expensive; reimbursement and insurance coverage may limit access.
• Regulatory oversight and clinical evidence—new therapies/devices need robust trials to prove safety and benefit.
• Patient adherence and access—especially for homecare, where proper usage, follow-up, and correct product selection are key.

Read the full industry analysis on InvestorsHangout

Keywords:
diabetic foot care market,
growth trends,
biologics,
device innovations,
homecare solutions

Umbrella Review: Traditional Chinese Medicine Improves Outcomes in Diabetic Foot Ulcers

Summary: A recent umbrella review published in Frontiers in Medicine assessed meta-analyses on Traditional Chinese Medicine (TCM) as adjunctive therapy for diabetic foot ulcers (DFUs). It finds that TCM interventions—especially topical/herbal formulations—are associated with improved healing outcomes and reduced complications, especially when treatments are applied over longer durations and in larger samples.

Key Highlights:

• Herbal treatments, ointments, and topical TCM formulations showed benefit in terms of wound size reduction, faster granulation, and fewer adverse events.
• Effect magnitudes tended to be higher when studies had longer follow-ups or more rigorous design quality.
• Safety was generally acceptable; some studies reported mild local irritation, but serious harms were rare.
• Review authors call for better standardization of herbal product preparation, ingredient quality, outcome metrics, and blinding in trials.

Read the umbrella review in Frontiers in Medicine

Keywords:
Traditional Chinese Medicine,
diabetic foot ulcer,
herbal formulations,
adjunct therapy,
recovery times

Knowledge, Attitude & Behaviour Toward Diabetic Foot Ulcers in East Java Community

Summary: A cross-sectional study conducted at Haji Regional General Hospital, East Java Province, Indonesia, assessed the community’s knowledge, attitude, and behaviour concerning diabetic foot ulcers (DFU). While many respondents had good attitudes, knowledge and behaviour/practice were frequently poor. The study found that knowledge level was not significantly associated with DFU occurrence, but attitude and behaviour/practice showed significant correlations.

Key Highlights:

• Poor knowledge common: 39.7% of respondents demonstrated poor knowledge about DFUs.
• Mixed attitude: 52.9% of respondents showed a good attitude toward prevention, despite gaps in knowledge and practice.
• Poor practices pervasive: Over half (52.9%) had poor behaviour/practice in preventive care for DFUs.
• Knowledge vs outcome: No statistically significant association between knowledge level and occurrence of DFU.
• Attitude & behaviour matter: Attitude and practice/behaviour were significantly associated with DFU presence.

Read the full study in IJSRM

Keywords:
diabetic foot ulcer,
knowledge,
attitude,
behaviour,
prevention practices,
East Java

Reusable Fiberglass & Polyester Total Contact Cast System for Plantar Diabetic Foot Ulcers: Efficacy & Cost-Effectiveness

Summary: A retrospective study from Sakarya University in Türkiye evaluated a reusable hybrid total contact cast (TCC) combining fiberglass and polyester for plantar diabetic foot ulcers unresponsive to standard care. Results showed high healing rates, consistent closure times across ulcer sites, and potential cost savings, positioning this system as a practical and sustainable off-loading option. (Frontiers in Endocrinology)

Key Highlights:

• Patient outcomes: Of 70 patients, 75.7% achieved complete wound closure, while 24.3% did not heal, with some requiring amputations.
• Ulcer location: Healing times were similar across forefoot, midfoot, and hindfoot ulcers, with no significant differences noted.
• Patient profile: Average patient age was 57 years; most had long-standing diabetes with peripheral neuropathy, and some presented with peripheral arterial disease.
• Cast design: The semi-rigid toe-to-knee cast combined durable fiberglass with softer polyester layers, designed for reusability and strength.
• Healing times: Median closure ranged from ~64.5 days (forefoot) to ~84.5 days (hindfoot), without statistically significant differences.
• Cost considerations: While a formal cost analysis was not included, the reusable design reduces material waste and offers potential economic advantages, particularly in resource-limited settings.

Read the full article in Frontiers in Endocrinology

Keywords:
diabetic foot ulcer,
total contact cast,
offloading,
reusable cast,
cost effectiveness,
wound healing

Reusable Fiberglass & Polyester Combined Total Contact Cast System for Plantar Diabetic Foot Ulcers: Efficacy & Cost-Effectiveness

Summary: A retrospective study at Sakarya University evaluated a hybrid total contact cast (TCC) system made of fiberglass and polyester that can be reused in the treatment of plantar diabetic foot ulcers unresponsive to standard care. Results showed strong healing rates, comparable performance across ulcer sites, and potential cost advantages, suggesting this system could be a sustainable option in wound care.

Key Highlights:

• Healing rates: 75.7% of patients (53 out of 70) achieved complete wound closure.
• Non-healing outcomes: Of 17 patients who did not heal, 9 required minor amputation and 1 required a major amputation.
• Time to heal: Median closure time was ~64.5 days for forefoot ulcers and ~84.5 days for hindfoot ulcers, with no significant differences by location.
• Patient profile: Average patient age was 57 years; many had long-standing diabetes with peripheral neuropathy, and 5 patients presented with peripheral arterial disease.
• Cast design: The semi-rigid toe-to-knee system combined a rigid fiberglass structure with soft polyester wraps. Casts were reused after inspection and cleaning.
• Cost and sustainability: While no formal economic analysis was completed, the reusable design reduces waste and may lower overall treatment costs.
• Limitations: As a single-center, retrospective study, results need validation in larger multicenter prospective trials. Patient comfort and adherence should also be explored further.

Read the full article in Frontiers in Endocrinology

Keywords:
diabetic foot ulcer,
total contact cast,
offloading,
reusable cast,
cost effectiveness,
wound healing time

Boruta Algorithm–Guided Antibiotic Selection in Antibiotic-Loaded Bone Cement for Diabetic Foot Ulcers: Microbiota and Susceptibility Analysis

Summary: A new study explores how machine learning can improve antibiotic choices in treating diabetic foot ulcer infections (DFIs) with antibiotic-loaded bone cement. By analyzing wound microbiota and using the Boruta algorithm, researchers identified antibiotics most effective against common pathogens and highlighted the role of patient age in guiding therapy.

Key Highlights:

• Study approach: Exudates from DFI wounds were cultured for bacterial identification and antibiotic susceptibility testing. The Boruta algorithm was applied to evaluate antibiotic effectiveness.
• Microbiota profile: Gram-positive organisms dominated, with Staphylococcus aureus frequently isolated.
• Antibiotic options: Gentamicin and tobramycin emerged as effective for gram-negative bacteria, while moxifloxacin, ampicillin, and quinupristin-dalfopristin showed strong performance against gram-positive isolates.
• Influence of age: Patient age significantly affected cumulative bacterial sensitivity, suggesting the need for age-aware antibiotic protocols.
• Clinical implications: Tailoring antibiotic selection to both pathogen profiles and patient demographics may improve DFI outcomes and reduce resistance risks.

Read the full article in Frontiers in Pharmacology

Keywords:
diabetic foot ulcer,
antibiotic-loaded bone cement,
Boruta algorithm,
bacterial microbiota,
antibiotic susceptibility,
wound infection management

Effectiveness of hyaluronic acid and its derivatives on diabetic foot ulcer: a systematic review and meta-analysis

Summary: This systematic review and meta-analysis assessed randomized controlled trials evaluating hyaluronic acid (HA) and its derivatives in the treatment of diabetic foot ulcers (DFUs). The authors found that HA use was associated with significantly higher complete healing rates and shorter healing times, without increasing adverse events. The analysis included 7 trials involving 444 patients and 456 ulcers.

Key Highlights:

• Healing rate improvement: HA use was linked to an odds ratio (OR) of ~3.92 for complete ulcer healing vs control.
• Faster healing: Time to healing was reduced (SMD ≈ –0.83) in HA-treated groups.
• Safety: No significant difference in adverse event rates compared to control treatments.
• Subgroup findings: Both HA alone and HA combined with autograft showed benefit, though heterogeneity was higher when autografts were involved.
• Limitations & future needs: Small number of trials, variable protocols, and moderate heterogeneity suggest need for larger, high-quality RCTs and standardization of HA formulations.

Read the full article on Frontiers in Endocrinology

Keywords:
Yao,
Xie,
Dai,
Huang,
hyaluronic acid,
diabetic foot ulcer,
meta-analysis,
clinical evidence

Mechanisms of microbial infection and wound healing in diabetic foot ulcer: pathogenicity in the inflammatory-proliferative phase, chronicity, and treatment strategies

Summary: This narrative review examines how microbial infection disrupts the healing phases of diabetic foot ulcers (DFUs), particularly from inflammation to proliferation, and explores treatment strategies. The authors integrate microbial pathogenesis (e.g. virulence, biofilms, polymicrobial synergy) with wound biology to highlight how infection drives chronicity and delay. They also suggest multidimensional therapeutic approaches combining systemic and localized strategies.

Key Highlights:

• Pathogenesis of DFU/DFI: Infections impair healing by promoting persistent inflammation, extracellular matrix degradation, impaired angiogenesis, and immune dysregulation.
• Biofilms & virulence: Biofilm formation and microbial virulence factors shield pathogens, resist antibiotics, and perpetuate inflammatory stimuli.
• Polymicrobial dynamics: Gram-positive, gram-negative, anaerobes, and fungi interact within wound microbiomes, often synergistically worsening outcomes.
• Therapeutic strategy framework: The authors advocate a combined approach—glycemic control, antimicrobial therapy tailored to pathogens, debridement, offloading, vascular support, and intelligent dressings.
• Smart dressing evolution: Future wound dressings should integrate responsive systems (pH, ROS), controlled drug release, and functional enhancements like oxygen delivery or antimicrobial action.

Read the full article on Frontiers in Endocrinology

Keywords:
Qi Wang,
Chuyu Liu,
Jing An,
Jing Liu,
Yongpeng Wang,
Yulan Cai,
diabetic foot ulcer,
infection mechanisms,
chronic wounds,
smart dressings

Multifaceted Antibiotic Resistance in Diabetic Foot Infections: A Systematic Review

Summary: This systematic review and limited meta-analysis (2014–2024) analyzed 28 studies to evaluate bacterial prevalence and antibiotic resistance patterns in diabetic foot infections (DFIs). The findings highlight high rates of multidrug resistance (MDR), associations with comorbidities, and the importance of culture-guided therapy in preventing treatment failure.

Key Highlights:

• Common pathogens: Staphylococcus aureus was the most frequent isolate, followed by Pseudomonas, Enterococcus, Enterobacter, and Escherichia coli.
• Resistance trends: High rates of both mono- and multidrug resistance were observed, with Acinetobacter showing the greatest MDR burden.
• Comorbidity correlations: Dyslipidemia, hypertension, nephropathy, peripheral vascular disease, prior amputation, and smoking were strongly linked with resistance profiles.
• Study limitations: Most studies originated from China and Malaysia, with male patients overrepresented, which may limit generalizability.
• Clinical impact: Empiric antibiotic use without culture testing risks treatment failure in MDR infections. Regular antibiogram surveillance and individualized therapy are essential for effective management.

Read the full article in Microorganisms (MDPI)

Keywords:
Weiqi Li,
Oren Sadeh,
Jina Chakraborty,
Emily Yang,
Paramita Basu,
Priyank Kumar,
diabetic foot infection,
antibiotic resistance,
multidrug resistance,
antimicrobial stewardship

Sequence LifeScience, Inc. Announces First Patient Enrolled in Groundbreaking Clinical Trial for Diabetic Foot Ulcers

Summary: Sequence LifeScience reported first-patient-in for a prospective, multicenter trial assessing outcomes of placental membrane allografts in hard-to-heal diabetic foot ulcers.

Key Highlights:

• Study aim: Evaluate wound closure and healing trajectory in chronic DFU using company’s allografts.
• Design: Prospective, multicenter clinical investigation focused on hard-to-heal ulcers.
• Rationale: Address persistent limb-loss risk and need for effective adjunctive biologics.

Read the press release on PR Newswire

Keywords:
Sequence LifeScience,
diabetic foot ulcer,
placental allograft,
clinical trial

The Role of Conjunctive Hyperbaric Oxygen Therapy in Decreasing Amputations in those with Diabetic Foot Ulcers: A Clinical Review

Summary: This clinical review appraises published evidence on the adjunctive use of hyperbaric oxygen therapy (HBOT) in diabetic foot ulcers (DFUs) and its impact on reducing major amputations and enhancing healing. Incorporating six comparative studies, the review synthesizes outcomes on wound size, infection, amputation rates, and mortality.

Key Highlights:

• HBOT as an adjunct to standard wound care demonstrated superior healing and reduced amputation in chronic DFUs.
• Meta-analyses included show consistent trends favoring HBOT over conventional therapy alone.
• The review process included filters, MeSH terms, and strict inclusion criteria to narrow to six high-quality studies.
• Authors call for larger prospective trials to better quantify risks, benefits, and optimal protocols.

Read full article

Keywords:
hyperbaric oxygen therapy,
diabetic foot ulcer,
amputation risk,
wound healing,
adjunctive therapy

Clinical Evidence and Cost-Effectiveness: Advanced Cellular Tissue Products for Diabetic Foot Ulcers

Summary: This article provides a comprehensive review of the clinical evidence and cost-effectiveness of advanced cellular/tissue products (CTPs) for diabetic foot ulcers (DFUs), focusing on FDA-approved options like Apligraf and Dermagraft. It demonstrates their superiority over standard care in achieving higher healing rates, shorter closure times, and reduced complications such as infections and amputations, while delivering significant long-term cost savings despite initial expenses. The discussion underscores the urgent need for early intervention in DFU management amid rising diabetes prevalence.

Key Highlights:

• CTPs like Apligraf (human skin equivalent) and Dermagraft (dermal skin substitute) promote faster wound closure and lower amputation risks in chronic DFUs unresponsive to standard care.
• Randomized trials show up to twice the healing rates with CTPs, supported by real-world data and meta-analyses confirming reduced hospitalization and infection risks.
• Economic analyses reveal per-patient savings of $5,253–$6,991 over 18 months, offsetting upfront costs through fewer emergency visits and inpatient stays.
• Challenges include high DFU recurrence (50% within 1 year) and the need for prompt adjunctive therapies to prevent 1 in 6 cases from leading to amputation.

Read full article

Keywords:
diabetic foot ulcers,
cellular tissue products,
Apligraf,
Dermagraft,
cost-effective wound care

Advanced MRI Markers: Predicting Diabetic Foot Ulcer Healing

Summary: Presented at the American Diabetes Association Scientific Sessions, this prospective observational study from Emory University explores noncontrast MRI perfusion imaging to forecast diabetic foot ulcer (DFU) healing. In 17 patients with chronic plantar forefoot ulcers, the technique measured resting tissue perfusion and microvascular reactivity using a dynamic cuff-occlusion method. Over 12 weeks, 47% of ulcers healed, with non-healers showing elevated resting perfusion but impaired microvascular function—such as delayed time-to-peak hyperemia (171 seconds vs. 101 seconds) and reduced tissue oxygen reserve (-6.5% vs. -3.2%). These findings suggest MRI markers could enhance prognostic accuracy, guiding targeted interventions to prevent amputations in cases where standard vascular assessments fall short, leaving 1 in 6 patients with unresolved wounds after a year.

Key Highlights:

• Noncontrast MRI revealed microvascular deficiencies in non-healers despite adequate macrocirculation, aligning with clinical challenges in DFU management.
• Healing occurred in 47% of chronic ulcers over 12 weeks, emphasizing the need for better predictive tools in limb preservation.
• Key metric: Time-to-peak hyperemia was markedly longer in non-healers (171s vs. 101s), indicating poorer reactive hyperemia for tissue repair.
• Tissue oxygen reserve capacity trended lower in non-healers (-6.5% vs. -3.2%), highlighting MRI’s potential to assess functional perfusion.
• Ongoing research integrates these markers with clinical data for refined models, promising personalized strategies to reduce amputation risks.

Read full article

Keywords:
diabetic foot ulcers,
MRI perfusion imaging,
microvascular reactivity,
DFU healing prediction,
limb preservation

Declining Trends: Incidence, Hospitalization, and Mortality in First-Ever Diabetic Foot Ulcers

Summary: This retrospective analysis from the UK’s CPRD GOLD primary care database (2007–2017) examines the incidence, hospitalization, and mortality trends for first-ever diabetic foot ulcers (DFUs) in 129,624 people with diabetes. For type 2 diabetes, the mean incidence rate was 2.5 per 1,000 person-years, with significant annual declines (IRR 0.97), alongside reduced hospitalization (8.2% average, OR 0.89) and 1-year mortality (11.7%, OR 0.94). No similar improvements were seen in type 1 diabetes (incidence 1.6 per 1,000 person-years). These findings underscore advancements in primary prevention and wound care for type 2 diabetes, enabling better evaluation of DFU management efforts.

Key Highlights:

• Incidence of first DFUs: 2.5 [95% CI: 2.1–2.9] per 1,000 person-years in type 2 diabetes; declined by 3% annually (IRR 0.97 [0.96–0.99]).
• Type 1 diabetes showed stable incidence at 1.6 [1.3–1.9] per 1,000 person-years (IRR 0.96 [0.89–1.04]).
• Hospitalization rates for type 2 diabetes averaged 8.2% [SD 4.7], with a 11% annual decline (OR 0.89 [0.84–0.94]).
• One-year all-cause mortality for type 2 diabetes was 11.7% [SD 2.2], decreasing 6% annually (OR 0.94 [0.89–0.99]).
• Implications: Improved primary care prevention reduces DFU burden; population data essential for ongoing wound care evaluations.

Read full article

Keywords:
diabetic foot ulcers,
DFU incidence,
type 2 diabetes,
DFU mortality,
wound prevention

Dehydrated Amnion Chorion Membrane vs. Standard Care for Diabetic Foot Ulcers: RCT Results

Summary: This prospective, multicentre, randomised controlled trial evaluated dehydrated Amnion Chorion Membrane (dACM) plus standard of care (SoC) versus SoC alone in 218 patients with complex diabetic foot ulcers (DFUs) extending into dermis or deeper. Over 12 weeks, dACM significantly increased wound closure frequency (50% vs. 35% at week 12, p=0.04), with a 48% higher probability (HR 1.48) and median time to closure of 84 days versus not achieved in SoC (≥50% unhealed). Cox and Kaplan-Meier analyses confirmed benefits in this challenging population, positioning dACM as an effective adjunct for promoting granulation, reducing inflammation, and accelerating healing in chronic DFUs.

Key Highlights:

• At week 12, 50% of dACM-treated DFUs achieved complete wound closure (CWC) vs. 35% in SoC, with superiority from week 4 (12% vs. 8%).
• Hazard ratio of 1.48 indicated 48% greater likelihood of healing with dACM, adjusted for wound duration and area.
• Median time to CWC: 84 days for dACM vs. not achieved in SoC group (p=0.04 via Kaplan-Meier).
• Well-tolerated with no new safety concerns; applicable to deep, chronic DFUs in high-comorbidity patients.
• Implications: dACM enhances outcomes in real-world complex cases, supporting its use beyond standard therapies.

Read full article

Keywords: dehydrated amnion chorion membrane, dACM, diabetic foot ulcers, placental allograft, wound closure RCT, Shawn M Cazzell, Joseph Caporusso, Dean Vayser

Challenging the Parabola Paradigm Post-Transmetatarsal Amputation

Summary: This oral abstract presented at the 2025 APMA National conference, led by Craig J. Verdin, DPM, reevaluates the longstanding “parabola paradigm” in post-transmetatarsal amputation (TMA) wound care for diabetic foot infections/gangrene. Analyzing 57 unilateral TMA patients retrospectively, the study substratifies residual parabolas (Types 1-4 per Bik et al.) and lengths (>50% preoperative), assessing impacts on complications and patient-reported outcomes (PROMs: LEFS for function, SF-12 for QoL). Findings reveal no significant ties to major complications or PROMs, only a weak correlation between unbalanced Type 4 parabolas and minor issues. It promotes function-driven, balanced parabolas over dogmatic length replication, and explores ray-preserving TMA variants for enhanced biomechanics, healing, and quality of life in podiatry limb salvage.

Key Highlights:

• Retrospective review of 57 TMAs at Georgetown University Hospital (2 years); no effect of parabola shape/length on major complications or PROMs/QoL.
• Weak correlation (p<0.05) between Type 4 (longer second metatarsal) and minor complications like reulceration due to uneven pressure.
• Historical McKittrick paradigm (1949) prioritizes Type 1 parabolas for propulsion; study calls it outdated, favoring balanced designs.
• Alternatives: Ray-preserving TMAs (e.g., first ray or first two rays per Suh et al., 2019) may optimize musculotendinous function and wound durability.
• Implications: Shift to PROMs/gait assessments in diabetic foot care for better outcomes, reducing reamputation risks in wound healing.

Read full article

Keywords: transmetatarsal amputation, residual parabola, diabetic foot amputation, limb salvage, ray-preserving TMA, Craig J Verdin, Ply C, Lava C

Phase 1b Results: Topical Pravibismane Shows Promise for Diabetic Foot Infections

Summary: This phase 1b randomized, multi-center, double-blind, placebo-controlled trial assessed topical pravibismane—a novel broad-spectrum anti-infective targeting biofilm-associated pathogens—as an adjunct to standard care for moderate to severe diabetic foot ulcer (DFU) infections in 53 patients over 4 weeks. Primarily evaluating safety, the study also captured efficacy signals, revealing nearly 3-fold greater wound size reduction, lower amputation rates, and microbiological clearance of key pathogens compared to placebo. Well-tolerated across doses with no significant safety issues, pravibismane addresses antimicrobial resistance and biofilm challenges, potentially reducing reliance on systemic antibiotics and supporting faster wound closure in this high-risk population.

Key Highlights:

• Trial design: Double-blind, placebo-controlled; topical application over 4 weeks; primary endpoint safety/tolerability; secondary: wound reduction, amputations, microbiology.
• Efficacy: ~3x greater ulcer size reduction vs. placebo; reduced lower extremity amputations; effective against biofilm-forming bacteria in DFUs.
• Safety: Well-tolerated with no significant concerns; supports advancement to larger trials.
• Expert quote (Benjamin Lipsky, MD): “We are pleased with the safety results and signals of clinical efficacy, which we believe warrant further clinical development… There is currently a major unmet need for new, easy-to-apply drug agents with multiple modes of activity to treat infection.”
• Expert quote (David Armstrong, DPM, PhD): “We are encouraged by the clinical efficacy signals… We need new agents that promote faster closing of infected wounds because we are currently dependent on an expensive, time-consuming, two-pronged approach.”
• Future: Sponsored by Microbion; data published in International Wound Journal (April 3, 2024); plans for further development in DFI treatment.

Read full article

Keywords: topical pravibismane, diabetic foot ulcer infection, biofilm targeting, wound size reduction, amputation prevention, Benjamin Lipsky, David Armstrong, Microbion

A Study to Evaluate the Safety and Efficacy of a Novel Wound Dressing in Patients With Diabetic Foot Ulcers

Summary: This ongoing Phase 2 randomized, controlled trial (NCT07206862) is assessing the safety and efficacy of a novel wound dressing compared to standard-of-care dressings in adults with chronic diabetic foot ulcers (DFUs) that have persisted for at least 4 weeks despite optimal therapy. Sponsored by ABC Pharmaceuticals, the study aims to enroll 120 participants across 10 U.S. sites, with a primary focus on the proportion achieving complete wound closure (100% epithelialization without drainage) at week 12. Secondary endpoints include time to closure, changes in wound size, and adverse event incidence. Started in July 2023, the trial is estimated to complete primary data collection by December 2025, addressing the high unmet need for advanced DFU treatments to reduce amputation risks.

Key Highlights:

• Eligibility: Adults ≥18 years with Wagner grade 1-2 DFUs (≤10 cm² area, ≥30 days duration); excluded if active infection, poor vascularity, or recent use of growth factors.
• Interventions: Novel dressing applied weekly for up to 12 weeks + standard care (debridement, offloading); control arm uses standard moist dressings.
• Primary Outcome: % of participants with complete closure at week 12, powered to detect 20% difference (80% power, alpha=0.05).
• Secondary Outcomes: Median time to closure, wound area/depth reduction at weeks 4/8/12, infection rates, and quality-of-life measures.
• Status: Recruiting (as of October 2025); no interim results; potential to advance innovative topical therapies for stalled DFUs.

View trial details

Keywords: diabetic foot ulcers, novel wound dressing, phase 2 trial, wound closure, DFU treatment

Use of Subatmospheric Pressure Systems in Diabetic Foot Ulcers

Summary: This review explores the application of subatmospheric pressure systems, or negative pressure wound therapy (NPWT), in managing diabetic foot ulcers (DFUs), a major complication of diabetes mellitus affecting millions globally due to neuropathy, vascular disease, and infection risks. Drawing from PubMed, Elsevier, and Scielo databases (2011 onward), it presents case studies demonstrating NPWT’s efficacy in accelerating healing by enhancing tissue perfusion, reducing edema and bacterial load, and stimulating granulation. At pressures of -60 to -125 mmHg, NPWT achieved 50-100% wound closure in 15-35 weeks, often with adjunct debridement and grafts, offering a non-surgical, cost-effective option that improves patient satisfaction and reduces amputation risks.

Key Highlights:

• Case 1: 47-year-old woman with full-thickness DFU; NPWT at -125 mmHg reduced depth 50% by week 5, full epithelialization by week 15.
• Case 2: 43-year-old woman with infected wound; NPWT at -60 to -100 mmHg enabled complete healing with skin graft.
• Case 3: 34-year-old man with 3.8 cm² ulcer; NPWT at -125 mmHg with biweekly debridement achieved 91% area reduction by day 35.
• Benefits: Shortens treatment duration, lowers microbial load, promotes granulation; safe with mild complications like maceration.
• Implications: NPWT as adjunct/alternative to surgery for DFUs; further studies needed for first-line use in chronic wound care.

Read full article

Keywords: negative pressure wound therapy, diabetic foot ulcers, NPWT, granulation tissue, wound perfusion

Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates Favorable Effects and Safety

Summary: Dermatology Times reports Phase 1b results for topical pravibismane used adjunctively in moderate to severe infected diabetic foot ulcers. The therapy was well-tolerated and associated with favorable healing signals alongside standard care, with the source article published in the International Wound Journal.

Key Highlights:

• Adjunct topical pravibismane vs placebo in infected DFUs.
• Safety and tolerability demonstrated across tested doses.
• Signals toward greater ulcer-size reduction and fewer ulcer-related amputations.
• Larger, confirmatory trials are warranted.

Read full article

Keywords: pravibismane, diabetic foot ulcer, International Wound Journal, Lipsky

Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates Favorable Effects and Safety

Summary:** In a phase 1b multi-center RCT, topical pravibismane—a broad-spectrum anti-infective targeting biofilm pathogens—was safe and well-tolerated in 53 patients with moderate-severe diabetic foot ulcer infections over 4 weeks as adjunct to standard care. It achieved ~3x greater ulcer size reduction, substantially lower amputation rates, and microbiological clearance of key bacteria vs placebo. The findings warrant further development for resistant infections in DFUs, where biofilms hinder 50% of cases.